Report on the enhanced surveillance of antimicrobial-resistant gonorrhea: Results from 2015 - 2017

Download in PDF format
(3.3 MB, 52 pages)

Organization: Public Health Agency of Canada

Published: 2021-02-23

Table of contents

Abbreviations

AMR
Antimicrobial resistance
AziR
Azithromycin resistant Neisseria gonorrhoeae
CARSS
Canadian Antimicrobial Surveillance System
CDC
US Centers for Disease Control and Prevention
CeDS
Neisseria gonorrhoeae with decreased susceptibility to cefixime
CephDS
Neisseria gonorrhoeae with decreased susceptibility to cephalosporins
CGSTI
Canadian Guidelines on Sexually Transmitted Infections
CipR
Ciprofloxacin resistant Neisseria gonorrhoeae
CMRNG
Chromosomal Mediated Resistant Neisseria gonorrhoeae
CNPHI
Canadian Network for Public Health Intelligence
CxDS
Neisseria gonorrhoeae with decreased susceptibility to ceftriaxone
EryR
Erythromycin resistant Neisseria gonorrhoeae
ESAG
Enhanced Surveillance of Antimicrobial-Resistant Gonorrhea
GASP
WHO Gonococcal Antimicrobial Surveillance Programme
gbMSM
Gay, bisexual and other men who have sex with men
GISP
US Gonococcal Isolate Surveillance Project
HESA
House of Commons Standing Committee on Health
MDR
Multi-drug resistant
MIC
Minimum Inhibitory Concentration
NAAT
Nucleic acid amplification test
NG-MAST
Neisseria gonorrhoeae multi-antigen sequence typing
NML
National Microbiology Laboratory
PenR
Penicillin resistant Neisseria gonorrhoeae
PHAC
Public Health Agency of Canada
Por
Porin gene
PPNG
Penicillinase Producing Neisseria gonorrhoeae
SpecR
Spectinomycin resistant Neisseria gonorrhoeae
ST
Sequence type
STBBI
Sexually transmitted bloodborne infection
STI
Sexually transmitted infection
TetR
Tetracycline resistant Neisseria gonorrhoeae
TOC
Test of Cure
TRNG
High-level, Plasmid mediated Tetracycline Resistant Neisseria gonorrhoeae
WGS
Whole genome sequencing
WHO
World Health Organization
XDR
Extensively drug resistant

Key Messages

  • Currently, Neisseria gonorrhoeae (N. gonorrhoeae), the bacteria that causes gonorrhea, is considered a serious public health threat since it has increasingly developed resistance to antimicrobial drugs recommended as treatment.
  • The Public Health Agency of Canada launched the Enhanced Surveillance of Antimicrobial-Resistant Gonorrhea (ESAG) initiative in 2013 to better understand the current trends of antimicrobial-resistant N. gonorrhoeae, and to support the development of treatment guidelines and public health interventions to minimize the spread of antimicrobial resistant gonorrhea in Canada.
  • In 2015 and 2016, data were collected from sentinel sites in five jurisdictions:  Calgary, Edmonton, Fort McMurray, Winnipeg and Halifax. In 2017, an additional jurisdiction, the Northwest Territories, was added.  Almost 95% (2,407/2,544) of the cases in ESAG were from Alberta.
  • From 2015 to 2017, ESAG collected 2,544 cultures from 2,120 cases (794 cultures from 668 cases in 2015, 832 cultures from 684 cases in 2016, and 918 cultures from 768 cases in 2017).
  • The majority of cases in each year were male (81.9% in 2015, 79.2% in 2016, and 81.4% in 2017) and less than 40 years old (83.8% in 2015, 84.6% in 2016, and 81.5% in 2017). Slightly less than half of the cases were among gay, bisexual and other men who have sex with men (gbMSM) in each year (47.8% in 2015 and 2016, and 45.1% in 2017). Nearly all female cases in all years reported male sexual partners.
  • Risk behaviours for ESAG cases saw some sizeable increases from 2015 to 2017, most likely due to better reporting. There was a 197% increase in those reporting sex work in the last 30 days (2.5% in 2015, 3.5% in 2016, and 7.6% in 2017).
  • There was a reduction in 2017 in the proportion of isolates with resistance to one or more antimicrobials 58.2% compared to 63.0% in 2015 and 65.8% in 2016.
  • The proportion of isolates with decreased susceptibility to cefixime declined from 0.8% in 2015 to 0.3% in 2017 with no isolates showing decreased susceptibility in 2016. Decreased susceptibility to ceftriaxone declined from 1.8% in 2015 to 0.6% in 2016 and 0.4% in 2017. The overall proportion resistant to azithromycin increased from 0.4% in 2015 to 1.9% in 2016 and dropped to 1.6% in 2017.
  • Among gbMSM, the preferred therapy of ceftriaxone and azithromycin was consistently prescribed more frequently to treat pharyngeal infections than to treat anogenital infections in all years (90.8% vs 87.5% in 2015; 83.2% vs 82.7% in 2016; and 85.5% vs 80.9% in 2017).
  • Adherence to the preferred or alternate treatments recommended by the Canadian Guidelines on Sexually Transmitted InfectionsReference 1 was above 85% for all treatment groups, with the exception of other adults with pharyngeal infections in 2015. In this category, 76.8% of cases received a preferred or alternate treatment in 2015; this proportion rose to 86.7% in 2016 and 86.9% in 2017.
  • With regards to molecular typing, ST7638 was the most prevalent sequence type in both 2015 (23.0%) and 2016 (11.4%), while ST5985 (22.4%) was the most prevalent ST in 2017. ST7638 was the primary ST identified among non-gbMSM and females, and isolates from this group are susceptible or have low-level resistance to tetracycline. Although 70% of ST5985 isolates were from non-gbMSM males, it was the primary ST identified among gbMSM males. The majority of these isolates are high-level, plasmid mediated tetracycline resistant N. gonorrhoeae (TRNG).
  • Engagement with other provinces/territories is ongoing with respect to potentially joining the Enhanced Surveillance of Antimicrobial-Resistant Gonorrhea project.

Introduction

In Canada and globally, rates of sexually transmitted infections (STI) continue to riseReference 2Reference 3 and remain a serious public health threatReference 4. Gonorrhea is the most commonly reported drug resistant STI and the second most common bacterial STI in Canada with over 29,000 cases reported in 2017Reference 5Reference 6. Worldwide, an estimated 87 million new cases of gonorrhea were reported in 2016Reference 2Reference 7. Over time, the causative organism, Neisseria gonorrhoeae (N. gonorrhoeae), has shown a remarkable ability to acquire antimicrobial resistance (AMR) through various evolutionary adaptationsReference 7Reference 8Reference 9Reference 10Reference 11Reference 12. In 2012, laboratory observed increases in decreased susceptibility to the “last line” class of antibiotic drugs, cephalosporins, along with high levels of resistance to penicillins, sulfonamides, tetracyclines, quinolones and macrolidesReference 13Reference 14 prompted the Public Health Agency of Canada to issue new recommendations for treatment of gonorrhea in the Canadian Guidelines on Sexually Transmitted InfectionsReference 1. Other international health agencies also updated their treatment guidelinesReference 7Reference 10Reference 12Reference 15Reference 16Reference 17. Since then, the recommended first-line treatment for uncomplicated anogenital gonorrhea in gay, bisexual and other men who have sex with men (gbMSM) and pharyngeal gonorrhea in all adults has been combination dual therapy with single doses of ceftriaxone (250 mg) injected intramuscularly (IM) and azithromycin (1 g) ingested orally (PO) Reference 1Reference 10Reference 18. Despite this effort, dual treatment failures have been reported in CanadaReference 19 and worldwideReference 3Reference 8Reference 17 due to high-level resistance.

The World Health Organization (WHO) predicted that drug resistance in N. gonorrhoeae could result in its eventual emergence as a “superbug”Reference 7 and that it could become untreatable due to resistance to all classes of antimicrobialsReference 20. Gonorrhea was listed as one of the three most critical public health threats in the United States by the Director of the US Centers for Disease Control and Prevention (CDC) in 2013Reference 4. The management of antimicrobial resistance has also been identified as a priority in the Public Health Agency of Canada (PHAC)’s Report on Plans and PrioritiesReference 21Reference 22Reference 23, Corporate Risk Profile, Operating Plan, as well as in the Standing Committee of Health (HESA) Study on the Status of Antimicrobial Resistance in Canada and Related RecommendationsReference 24. It has also been highlighted in the Agency’s Canadian Antimicrobial Resistance Surveillance System (CARSS)Reference 25Reference 26 reporting as well as in its Pan-Canadian Framework for Action:  Reducing the Health Impact of Sexually Transmitted and Blood-borne Infections in Canada by 2030Reference 27.

The definition of multi-drug resistantFootnote a (MDR-GC) and extensively-drug resistantFootnote b gonococci (XDR-GC) were recently updated to reflect the current Canadian guidelinesReference 14Reference 17. In isolates tested by the NML, the proportion of MDR-GC increased from 6.2% in 2012Reference 13Reference 17 to 12.2% in 2017Reference 9, and the proportion of XDR-GC remained low (less than 1%)Reference 9. Travel-related ceftriaxone-resistant gonorrhea has also been reported in Canada (Quebec, 2017; Alberta, 2018)Reference 28Reference 29Reference 30. The cases were genetically similar to the N. gonorrhoeae Japanese strain FC428 and were related to travel within AsiaReference 14Reference 17Reference 28Reference 29 The 2017 case was successfully treated using the current recommended therapy, while the 2018 case required treatment with gentamicin and azithromycin before being successfully cured, denoting the gravity of gonorrhea becoming an untreatable infectionReference 12Reference 14Reference 28Reference 29.

Antimicrobial resistance testing is an important component of gonococcal (GC) surveillance as it:  (i) allows for the identification and characterization of resistant isolates in circulation; and (ii) monitors changes in the proportion of isolates that are resistant, which is vital for informing clinical treatment guidelines. Currently, the regional laboratories in all ten provinces employ culture for a proportion of the total gonorrhea tests done within their jurisdictions, but nucleic acid amplification testing (NAAT) is the preferred testing method for diagnosis in these jurisdictions. The use of culture for antimicrobial resistance (AMR) testing is a standard laboratory practice for all positive gonorrhea isolates detected by culture worldwide, including Canada. However, as the majority of GC cases (70-78%) are not cultured, AMR data are not available for these casesReference 9Reference 17. Most jurisdictions with provincial laboratories that perform culture also perform AMR testing on all positive cultures. Resistant isolates, as well as all isolates from jurisdictions that do not conduct AMR testing, are sent from the provincial/territorial laboratory to the National Microbiology Laboratory (NML) for a standard panel of AMR testing. However, the submission of isolates submitted to the NML varies by jurisdiction, resulting in a lack of representativeness. The NML also performs N. gonorrhoeae multi-antigen sequence typing (NG-MAST) on isolates received as a means to describe the circulating strains of gonorrhea across Canada. Sex, age of patient, province, and anatomic site of isolation are the only epidemiological data collected on these isolates.

Gonorrhea has been a nationally notifiable disease since 1924 in Canada; however, the amount and quality of information collected and reported to PHAC through routine surveillance are limited. Comprehensive national epidemiological data for antimicrobial-resistant gonorrhea isolates are currently not available; limiting the ability to assess risk factors associated with AMR and guide treatment recommendations at a national level. There are also significant difficulties in deriving a valid denominator to estimate the prevalence and patterns of AMR in Canada. The establishment of a pan-Canadian, standardized approach to the surveillance of antimicrobial-resistant gonococci, combining both epidemiologic and laboratory data would provide better representation across the country and greater confidence in the estimation of the proportion of drug-resistant isolates. Coupled with NG-MAST sequence typing and enhancement in data quality, this approach could also provide an opportunity to detect unusual clusters, facilitate timelier outbreak response, and design evidence-informed treatment guidelines.

In 2013, the Centre for Communicable Diseases and Infection Control (CCDIC), in partnership with the NML and three provinces (Alberta, Manitoba and Nova Scotia), launched the pilot phase of the Enhanced Surveillance of Antimicrobial-Resistant Gonorrhea (ESAG). Alberta, which already collected data relevant to N. gonorrhoeae antimicrobial resistance (GC-AMR), was the first participating jurisdiction. Winnipeg and the Capital District Health Authority in Nova Scotia (now the Nova Scotia Health Authority – Central Zone), began collecting data in 2014. Additionally, in 2018, the Northwest Territories joined ESAG.

Project Goal

The overall goal of this integrated epidemiology-laboratory surveillance system is to improve the understanding of current levels and trends of antimicrobial resistant gonorrhea in Canada and to provide better evidence to inform the development of treatment guidelines and public health interventions to minimize the spread of antimicrobial resistant N. gonorrhoeae.

Project Deliverables

The objectives of this surveillance system are to:

  1. Increase the number of gonococcal cultures performed at participating sentinel sites in order to improve monitoring of gonorrhea AMR;
  2. Monitor antimicrobial susceptibilities of N. gonorrhoeae among newly diagnosed culture-confirmed gonorrhea cases and cases of potential treatment failureFootnote c;
  3. Collect additional epidemiological data (demographics and risk factors) on people who provided samples for a gonococcal culture, including newly diagnosed culture-confirmed gonorrhea cases and cases of treatment failure, to determine the risk factors for gonorrhea AMR in these populations;
  4. Collect data on the drugs prescribed to treat gonorrhea; and
  5. Identify the sequence types of circulating antimicrobial-resistant N. gonorrhoeae through NG-MAST typing.

Methods

Case Definitions

The national case definition for gonorrhea was used for ESAG cases and consists of laboratory evidence of detection of Neisseria gonorrhoeae by culture or nucleic acid testingReference 31.

An “ESAG case” refers to a patient 16 years of age and older from whom a specimen (or specimens) collected within thirty days that met the national case definition for gonorrhea. All positive cultures from participating sentinel sites were included in ESAG.

The case definition for treatment failure used in ESAG was the absence of sexual contact during the post-treatment period AND one of the following:  (1) gram-negative intracellular diplococci at least 72 hours post-treatmentReference 7; (2) positive N. gonorrhoeae culture at least 72 hours post treatment; or (3) positive N. gonorrhoeae NAAT at least 2-3 weeks post treatmentReference 1.

Data Collection

Data were collected from sentinel sites in six jurisdictions: Calgary, Edmonton, Fort McMurray, Winnipeg, Halifax, and the Northwest Territories. Sentinel sites were selected by participating provincial/local health authorities and were sexual health or STI clinics or healthcare providers with the capacity to collect cultures for testing and to provide enhanced epidemiological and clinical data. Cultures were collected by sentinel sites according to their provincial guidelines on gonorrhea testing. Where possible, the number of gonococcal cultures performed was increased in order to improve monitoring of antimicrobial-resistant gonorrhea.

Data were extracted from routine/enhanced case report forms of ESAG-eligible gonorrhea cases reported to public health officials by participating sentinel sites. The data elements collected as part of epidemiological information included information on demographics (e.g., age, sex, site of infection, and province), sexual partner(s) characteristics, risk behaviours, reasons for visit, and treatment. These data were later linked to laboratory testing data from the NML, such as antimicrobial susceptibility and sequence typing data, further described below.

Sentinel sites submitted isolates to provincial public health laboratories for antimicrobial susceptibility testing, which were then forwarded on to the NML where sequence typing and susceptibility testing, on an expanded panel of antimicrobials, were performed. For jurisdictions that rely on the NML for their susceptibility testing, all isolates from the sentinel sites were sent to the NML for testing. Data for isolates that met the eligibility criteria were submitted to ESAG. Epidemiological data were also submitted for all susceptible isolates; however, only a portion of the susceptible isolates were sent to the NML for re-testing.

Both epidemiological and laboratory data were entered or uploaded into a password-protected, web-accessible, jurisdictionally-filtered database hosted on the Canadian Network for Public Health Intelligence (CNPHI) platform. Necessary steps were taken to ensure accurate linkage of epidemiological data, entered by the sentinel sites, to laboratory results, entered by the NML, in this database. A designated ID number, in lieu of that patient's name, was used to link the data.

Laboratory Methods

Antimicrobial Susceptibility Testing for Isolates

Minimum inhibitory concentration (MIC), the minimum concentration of antibiotic that will inhibit the growth of the organism, was determined for ceftriaxone, cefixime, azithromycin, ciprofloxacin, erythromycin, penicillin, tetracycline and spectinomycin on all N. gonorrhoeae isolates using agar dilution or, for the Alberta susceptible isolates not sent to the NML, Etest® (BioMerieux, Laval, Quebec). Interpretations were based on the Clinical and Laboratory Standards Institute (CLSI) breakpointsFootnote 32 except for:  cefixime decreased susceptibility MIC ≥ 0.25 mg/LReference 7; ceftriaxone decreased susceptibility MIC ≥ 0.125 mg/LReference 7; and erythromycin resistance MIC ≥ 2.0 mg/LReference 33 (refer to Appendix A and Appendix B for details).

Sequence Typing for Isolates

Sequence typing was determined for all cultures submitted to the NML using the N. gonorrhoeae multi-antigen sequence type (NG-MAST) methodReference 34 that incorporates the amplification of the porin gene (por) and the transferrin-binding protein gene (tbpB). DNA sequences of both strands were edited, assembled and compared using DNAStar, Inc. software. The resulting sequences were submitted to the NG-MAST website to determine the sequence types (ST). Concentrated NG-MAST porB and tbpB sequences were aligned using ClustalWReference 35 and a maximum likelihood phylogenetic tree was generated using MEGA 6.06 based on the Tamura-Nei modelReference 36. NG-MAST testing was not performed on the susceptible isolates whose cultures were not submitted to the NML.

Data Analysis

Although ESAG was initiated in 2013, this report is limited to 2015 through 2017 data when all five sites were active participants. Frequencies were calculated for cases with positive cultures. Negative cultures (such as those from a follow-up visit or test-of-cure) were excluded.

For most analyses, only one culture per case was included. When more than one culture per case was submitted, the culture retained for analysis was based on a hierarchy of site of infection:  the pharyngeal isolate was prioritized, followed by rectal, urethral, and cervical samples in that order. This hierarchy was determined through consensus with ESAG sites and stakeholders. However, all cultures were retained for analysis when describing the sites of infection overall.

To improve data quality, a derived sexual behaviour variable was created to supplement the self-reported “sex of sexual partner.” In addition to including males who self-reported sexual partner as male or both male and female, the derived “gay, bisexual and other men who have sex with men (gbMSM)” variable includes males who did not provide information on the sex(es) of their sexual partner(s), but had a rectal infection. “Non-gbMSM” was defined as males who either only reported female partners or males who did not report any male sexual partners and did not have a rectal infection. “Male Unknown” refers to males who did not provide sexual partner information, who also did not have a rectal infection. Female and transgender cases were grouped together for antimicrobial susceptibility analysis due to there being only one transgender case, which had a pharyngeal site of infection. In the treatment section, cases are categorized as gbMSM (using the same derived gbMSM definition) and as Other Adults, which matches the categories used in the Canadian Guidelines on Sexually Transmitted InfectionsReference 1 (Other Adults includes non-gbMSM males and females, but excludes males with unknown sexual behaviour).

Table 1 shows how the ESAG data were categorized to arrive at the total number of cultures (including multiple isolates per case), and the total number of cases.

Table 1. Cultures from participating jurisdictions, ESAG 2015-2017
Jurisdiction Primary Culture Duplicate Cultures All Cultures
2015 2016 2017 Overall 2015 2016 2017 Overall 2015 2016 2017 Overall
Alberta 641 629 726 1,996 123 143 145 411 764 772 871 2,407
Manitoba 12 23 8 43 3 3 2 8 15 26 10 51
Nova Scotia 14 28 29 71 0 2 3 5 14 30 32 76
Northwest Territories 1 4 5 10 0 0 0 0 1 4 5 10
Total 668 684 768 2,120 126 148 150 424 794 832 918 2,544

Results

Case Characteristics

The proportion of gbMSM males to non-gbMSM males remained relatively constant from 2015 to 2017, with a ratio of 1.4:1 in 2015, 1.5:1 in 2016 and 1.3:1 in 2017. The proportion of males to females also remained relatively constant in both 2015 and 2017, after a slight decrease in 2016, with a ratio of 4.5:1 in 2015, 3.9:1 in 2016 and 4.4:1 in 2017 (Table 2 and Figure 1).

Table 2. Breakdown of ESAG isolates by province/territory, year and sex or sexual behaviour, ESAG 2015-2017Table 2 Footnote a
Sex or Sexual Behaviour Alberta Manitoba Nova Scotia Northwest Territories Overall
2015 2016 2017 2015 2016 2017 2015 2016 2017 2015 2016 2017 2015 2016 2017
gbMSM Male 307 297 331 5 13 1 7 17 14 0 0 0 319 327 346
(47.9) (47.2) (45.6) (41.7) (56.5) (12.5) (50.0) (60.7) (48.3) (0.0) (0.0) (0.0) (47.8) (47.8) (45.1)
Non-gbMSM Male 217 202 261 5 3 0 0 3 7 0 4 3 222 212 271
(33.9) (32.1) (36.0) (41.7) (13.0) (0.0) (0.0) (10.7) (24.1) (0.0) (100.0) (60.0) (33.2) (31.0) (35.3)
Female 116 127 132 1 5 1 4 8 8 0 0 2 121 140 143
(18.1) (20.2) (18.2) (8.3) (21.7) (12.5) (28.6) (28.6) (27.6) (0.0) (0.0) (40.0) (18.1) (20.5) (18.6)
Male - Unknown 1 2 2 1 1 6 3 0 0 1 0 0 6 3 8
(0.2) (0.3) (0.3) (8.3) (4.3) (75.0) (21.4) (0.0) (0.0) (100.0) (0.0) (0.0) (0.9) (0.4) (1.0)
Total 641 629 726 12 23 8 14 28 29 1 4 5 668 684 768
Table 2 Footnote a

The overall total in 2016 included a transgender individual with a pharyngeal infection and an unknown individual with a rectal infection.

Table 2 Return to footnote a referrer

Figure 1. Breakdown of ESAG isolates by year and sex or sexual behaviour, ESAG 2015-2017

figure 01

Text description

The bar chart presents the number of ESAG isolates demonstrating either decreased susceptibility or resistance to selected antimicrobials by year and sex or sexual behaviour groupings. The horizontal axis represents the year while the vertical axis represents the number of isolates.

Sex or Sexual Behaviour 2015 2016 2017
gbMSM male 319 327 346
Non-gbMSM male 222 212 271
Female 121 140 143
Male unknown 6 3 8

From 2015 to 2017, ESAG captured 2,544 cultures from 2,120 cases. Twenty percent (n=424) of these cases had multiple (two or three) positive isolates from different sites of infection (Table 1). The age distribution was very similar in all years. From 2015 to 2017, the majority of cases were less than 40 years old (83.8% in 2015, 84.6% in 2016, and 81.5% in 2017) and the mean ages were 30.6 years in 2015, 31.3 years in 2016, and 32.6 in 2017. The largest increase was in the 35 to 39 year age group (81% increase from 2015 to 2017) (Table 3).

Risk behaviours for ESAG cases increased in 2017 with 7.6% reporting sex work in the last 60 days and 9.5% indicating that it was likely that they acquired the infection while travelling out of province (Table 3). This represents a 197% increase in those reporting sex work and a 1487% increase in those reporting travel-related infection, compared to 2015. These increases are most likely due to better reporting in 2017 when more information about out-of-province travel was collected more consistently in the reporting jurisdictions.

Table 3. Demographics and risk characteristics of cases diagnosed with gonorrhea by culture at participating sites, ESAG 2015-2017Table 3 Footnote a
Case Characteristics 2015 2016 2017
N % N % N %
Age
16 - 19 years 48 7.2 35 5.1 28 3.6
20 - 24 years 150 22.5 129 18.9 109 14.2
25 - 29 years 183 27.4 195 28.5 205 26.7
30 - 34 years 121 18.1 150 21.9 163 21.2
35 - 39 years 58 8.7 70 10.2 121 15.8
40 - 44 years 33 4.9 34 5.0 58 7.6
45 - 49 years 32 4.8 23 3.4 34 4.4
50 - 54 years 17 2.5 26 3.8 22 2.9
55 - 59 years 13 1.9 12 1.8 17 2.2
60+ years 13 1.9 10 1.5 11 1.4
Total 668 684 768
Sex Work
Yes 17 2.5 24 3.5 58 7.6
No 646 96.7 631 92.3 661 86.1
Refused to answer 0 0.0 0 0.0 3 0.4
Unknown 5 0.7 29 4.2 18 2.3
Total 668 684 768
Travel-Related Infection
Yes 4 0.6 2 0.3 73 9.5
No 660 98.8 5 0.7 19 2.5
Unknown 4 0.6 677 99.0 676 88.0
Total 668 684 768
Table 3 Footnote a

In 2017, 3.6% of cases were not asked whether the individual participated in sex work (Not Asked (data was not collected), N=28).

Table 3 Return to footnote a referrer

Reason for Visit

Among gbMSM, the primary reason for the initial clinic visit in all years was in response to signs/symptoms increasing from 41.7% in 2015 to 56.6% in 2017. There was a 50% decrease in visits due to case contact between 2015 and 2017 (from 30.1% to 15.0%, respectively). gbMSM were the group with the highest level of STI screening, accounting for approximately one-quarter of visits in all three years compared to less than 3% among non-gbMSM and approximately one-fifth among females. Non-gbMSM, conversely, rarely identified screening as the reason for seeking care; signs/symptoms remained the primary reason for non-gbMSM male visits in all years, accounting for more than 88% of cases in each year. The primary reason for visits among females was in response to signs/symptoms in 2016 (52.9%) and 2017 (54.5%), compared to case contact in 2015 (42.1%), with corresponding increases in the “unknown” and “other” categories (Table 4).

Table 4. Reasons for which reported cases sought care (initial visits) at participating sites, ESAG 2015-2017
Reason for Initial Visit 2015 2016 2017 Overall
N % N % N % N %
gbMSM Male
Signs/Symptoms 133 41.7 159 48.6 196 56.6 488 49.2
Case Contact 96 30.1 64 19.6 52 15.0 212 21.4
STI Screening 74 23.2 84 25.7 86 24.9 244 24.6
Unknown 8 2.5 7 2.1 3 0.9 18 1.8
OtherTable 4 Footnote a 0 0.0 0 0.0 7 2.0 7 0.7
Total 319 327 346 992
Non-gbMSM Male
Signs/Symptoms 196 88.3 192 90.6 258 95.2 646 91.6
Case Contact 16 7.2 7 3.3 4 1.5 27 3.8
STI Screening 5 2.3 1 0.5 5 1.8 11 1.6
Unknown 0 0.0 5 2.4 1 0.4 6 0.9
OtherTable 4 Footnote a 0 0.0 0 0.0 0 0.0 0 0.0
Total 222 212 271 705
Female
Signs/Symptoms 47 38.8 74 52.9 78 54.5 199 49.3
Case Contact 51 42.1 27 19.3 22 15.4 100 24.8
STI Screening 16 13.2 31 22.1 22 15.4 69 17.1
Unknown 1 0.8 2 1.4 11 7.7 14 3.5
OtherTable 4 Footnote a 0 0.0 0 0.0 7 4.9 7 1.7
Total 121 140 143 404
OverallTable 4 Footnote b
Signs/Symptoms 377 56.4 425 62.1 532 69.3 1,334 62.9
Case Contact 164 24.6 98 14.3 78 10.2 340 16.0
STI Screening 95 14.2 116 17.0 113 14.7 324 15.3
Unknown 9 1.3 16 2.3 15 2.0 40 1.9
OtherTable 4 Footnote a 0 0.0 0 0.0 14 1.8 14 0.7
TotalTable 4 Footnote c 668 684 768 2,120
Table 4 Footnote a

Other includes “Getting IUD”, “Requirement of Choices Program”, and “Treatment”.

Table 4 Return to footnote a referrer

Table 4 Footnote b

Overall numbers also include data from cases where sex and sexual behavior were not provided (2015=6; 2016=4; and 2017=8).

Table 4 Return to footnote b referrer

Table 4 Footnote c

Seven follow-up cases have been excluded from the 2015 Grand Total.

Table 4 Return to footnote c referrer

Site of Infection

From 2015 to 2017, there were 2,544 isolates from 2,120 culture-confirmed gonorrhea cases. Anatomic site samples were based on provincial screening guidelines or exposure. Isolates from female cases were primarily genital (47.0% in 2015, 46.4% in 2016 and 41.0% in 2017). Infections from non-gbMSM males were almost exclusively genital in all years (>95% each year). Isolates from gbMSM males were fairly equally distributed among the rectum, genital and pharynx in all three years but with a greater proportion of rectal isolates in 2015 (37.1%) and 2016 (41.4%) by a small margin (Table 5).

Table 5. Site in infection table 5 Footnote a by sex or sexual behaviour from all cultures, ESAG 2015-2017
Sex or Sexual Behaviour 2015 2016 2017 Overall
N % N % N % N %
gbMSM Male
Rectum 147 37.1 164 41.4 144 33.7 455 37.3
Pharynx 119 30.1 105 26.5 145 34.0 369 30.3
Genital 130 32.8 127 32.1 138 32.3 395 32.4
Total 396 100 396 100 427 100 1,219 100
Non-gbMSM Male
Rectum 0 0.0 5 2.3 1 0.4 6 0.8
Pharynx 4 1.8 7 3.2 5 1.8 16 2.2
Genital 220 98.2 207 94.5 267 97.8 694 96.9
Total 224 100 219 100 273 100 716 100
Female
Rectum 37 22.0 54 25.8 62 30.0 153 26.2
Pharynx 52 31.0 58 27.8 59 28.5 169 28.9
Genital 79 47.0 97 46.4 85 41.0 261 44.7
Other table 5 Footnote b 0 0.0 0 0.0 1 0.5 1 0.2
Total 168 100 209 100 207 100 584 100
Overall table 5 Footnote c
Rectum 184 23.2 226 27.2 210 22.9 620 24.4
Pharynx 177 22.3 173 20.8 211 23.0 561 22.1
Genital 433 54.5 432 51.9 496 54.0 1,361 53.5
Other table 5 Footnote b 0 0.0 1 0.1 1 0.1 2 0.0
Grand Total 794 100 832 100 918 100 2,544 100
Table 5 Footnote a

Sites of infection of duplicate isolates are included in this table.

Table 5 Return to footnote a referrer

Table 5 Footnote b

Other includes “Eye”.

Table 5 Return to footnote b referrer

Table 5 Footnote c

Overall numbers include data from cases where sex and sexual behavior were not provided (2015=6; 2016=5; and 2017=8).

Table 5 Return to footnote c referrer

Antimicrobial Susceptibility

Overall, 37.0% (247/668) of the 2015 isolates, 34.2% (234/684) of the 2016 isolates and 41.8% (321/768) of the 2017 isolates were susceptible to all antimicrobials. The proportion of the 2015-2017 isolates that demonstrated decreased susceptibility or resistance to only one antimicrobial was 27.1% (181/668), 23.7% (162/684), and 38.7% (297/768) respectively. The proportion of 2015-2017 isolates that demonstrated decreased susceptibility or resistance to two or more antimicrobials was 35.9% (240/668), 42.1% (288/684), and 19.5% (150/768) respectively. (Table 6 and Figure 2).

Table 6. Drug resistance and decreased susceptibility to selected antimicrobials by province/territory, ESAG 2015-2017
Susceptibility Alberta Manitoba Nova Scotia Northwest Territories Overall
2015 2016 2017 2015 2016 2017 2015 2016 2017 2015 2016 2017 2015 2016 2017
Susceptible to all 240 219 305 4 6 2 3 8 13 0 1 1 247 234 321
(37.4) (34.8) (42.0) (30.8) (26.1) (25.0) (21.4) (28.6) (44.8) (0.0) (25.0) (20.0) (37.0) (34.2) (41.8)
R/DSTable 6 Footnote a to one 172 144 288 4 11 2 5 7 7 1 0 0 181 162 297
(26.8) (22.9) (39.7) (30.8) (47.8) (25.0) (35.7) (25.0) (24.1) (100.0) (0.0 (0.0 (27.1) (23.7) (38.7)
R/DSTable 6 Footnote a to two or more 229 266 133 5 6 4 6 13 9 0 3 4 240 288 150
(35.7) (42.3) (18.3) (38.5) (26.1) (50.0) (42.9) (46.4) (31.0) (0.0) (75.0) (80.0) (35.9) (42.1) (19.5)
Total 641 629 726 13 23 8 14 28 29 1 4 5 668 684 768
Table 6 Footnote a

R/DS: Resistance or Decreased Susceptibility

Table 6 Return to footnote a referrer

Figure 2. Drug resistance and decreased susceptibility to selected antimicrobials, ESAG 2015-2017

figure 2

*R/DS: Resistance or Decreased Susceptibility

Text description

The bar chart presents the proportion of isolates that were either susceptible to all antimicrobials tested or demonstrated resistance or decreased susceptibility to one or more antimicrobials. The horizontal axis represents the year while the vertical axis represents the proportion of isolates.

Susceptibility 2015 2016 2017
Susceptible to all 37.0 34.2 41.8
Resistant/Decreased susceptibility to one 27.1 23.7 38.7
Resistant/Decreased susceptibility to two or more 35.9 42.1 19.5

CefiximeFootnote d

Overall, 0.8% (6/794) of isolates had decreased susceptibility to cefixime (MIC ≥ 0.25 mg/L) in 2015, declining to 0.3% (2/918) in 2017 with no isolates demonstrating decreased susceptibility in 2016 (Table 7, Appendix C and Appendix D). Seventy-five percent (6/8) of all isolates demonstrating decreased susceptibility were from Alberta with the remaining two isolates coming from Manitoba (1/8) and Nova Scotia (1/8). In 2015, 0.8% (3/396) of isolates from gbMSM and 0.4% (1/224) from non-gbMSM had decreased susceptibility to cefixime which dropped to 0.3% (1/348) and 0% (0/271) respectively in 2017, The proportion of female isolates demonstrating decreased susceptibility to cefixime increased to 0.7% (1/144) in 2017 from 0% in both 2015 and 2016 (Figure 3, Table 7, Table 8, Appendix C and Appendix D).

The proportion of pharyngeal isolates demonstrating decreased susceptibility to cefixime amongst all males dropped to 0.7% (1/152) in 2017 from 3.2% (4/125) in 2015 with zero cases reported in 2016. Among females, the proportion of decreased susceptibility to cefixime for pharyngeal isolates increased from 0% in both 2015 and 2016 to 1.7% (1/59) in 2017 (Figure 4, Table 8 and Appendix D).

Figure 3. Distribution of decreased susceptibility to cefixime by sex or sexual behaviour, ESAG 2015-2017

figure 3

Text description

The bar chart presents the proportion of ESAG isolates with decreased susceptibility to cefixime by sex or sexual behaviour groupings. The horizontal axis represents the year while the vertical axis represents the decreased susceptibility proportion.

Sex or Sexual Behaviour 2015 2016 2017
gbMSM male 0.6 0.0 0.3
Non-gbMSM male 0.5 0.0 0.0
Female 0.0 0.0 0.7
Overall 0.7 0.0 0.3

Figure 4. Distribution of decreased susceptibility to cefixime by sex and infection site, ESAG 2015-2017

figure 4

Text description

The bar chart presents the proportion of ESAG isolates with decreased susceptibility to cefixime by sex and infection site groupings. The horizontal axis represents the year while the vertical axis represents the decreased susceptibility proportion.

Sex or Sexual Behaviour and Infection Site 2015 2016 2017
Cervix 0.0 0.0 0.0
Urethra 0.3 0.0 0.0
Pharynx – Female 0.0 0.0 1.7
Pharynx – Male 3.2 0.0 0.7
Rectum – Female 0.0 0.0 0.0
Rectum – Male 0.0 0.0 0.0
Overall 0.7 0.0 0.3

CeftriaxoneFootnote d

Overall, 1.8% (14/794) of ESAG isolates had decreased susceptibility to ceftriaxone in 2015, dropping to 0.6% (4/684) in 2016 and 0.4% (3/771) in 2017 (Table 7, Appendix C and Appendix D). Eighty-eight percent (18/21) of all isolates demonstrating decreased susceptibility were from Alberta, 10% (2/21) were from Manitoba and the remaining 5% (1/21) were from Nova Scotia. There was an 80% decrease in occurrence of decreased susceptibility to ceftriaxone in isolates obtained from gbMSM males from 2.8% (11/396) to 0.6% in both 2016 and 2017 (2/327 and 2/348 respectively). There was only one ESAG isolate from a female demonstrating decreased susceptibility to ceftriaxone in 2016 (0.7%), with no isolates in either 2015 or 2017 (Figure 5, Table 7, Table 8, Appendix C and Appendix D).

The proportion of pharyngeal isolates demonstrating decreased susceptibility to ceftriaxone among males dropped to 1.3% (2/152) in 2017 from 6.4% (8/125) in 2015 with no cases reported in 2016. The proportion of rectal isolates from females was 2.9% (1/35) in 2016 with zero cases reported in both 2015 and 2017 (Figure 6 and Appendix D).

Figure 5. Distribution of decreased susceptibility to ceftriaxone by sex or sexual behaviour, ESAG 2015-2017

figure 5

Text description

The bar chart presents the proportion of ESAG isolates with decreased susceptibility to ceftriaxone by sex or sexual behaviour groupings. The horizontal axis represents the year while the vertical axis represents the decreased susceptibility proportion.

Sex or Sexual Behaviour 2015 2016 2017
gbMSM male 2.8 0.6 0.6
Non-gbMSM male 0.5 0.5 0.0
Female 0.0 0.7 0.0
Overall 1.8 0.6 0.4

Figure 6. Distribution of decreased susceptibility to ceftriaxone by sex and infection site, ESAG 2015-2017

figure 6

Text description

The bar chart presents the proportion of ESAG isolates with decreased susceptibility to ceftriaxone by sex and infection site groupings. The horizontal axis represents the year while the vertical axis represents the decreased susceptibility proportion.

Sex or Sexual Behaviour and Infection Site 2015 2016 2017
Cervix 0.0 0.0 0.0
Urethra 0.3 0.7 0.3
Pharynx – Female 0.0 0.0 0.0
Pharynx – Male 6.4 0.0 1.3
Rectum – Female 0.0 2.9 0.0
Rectum – Male 2.7 0.7 0.0
Overall 1.8 0.6 0.4

AzithromycinFootnote d

In 2015, 0.4% (3/794) of all isolates obtained from ESAG cases were resistant to azithromycin. The proportion increased to 1.9% (13/684) in 2016 and 1.6% (12/771) in 2017 (Table 7, Appendix C and Appendix D). Due to the sample size, almost 90% (25/28) of all azithromycin isolates identified were from Alberta, with the remaining three isolates identified as coming from Nova Scotia in 2016 (Table 7). The proportion of azithromycin resistant isolates from gbMSM males increased from 0.3% (1/396) in 2015 to 2.3% (8/348) in 2017. In isolates from non-gbMSM males, the proportion increased slightly from 0.4% (1/224) in 2015 to 0.7% (2/271) in 2017, with no isolates in 2016. The proportion of isolates from females increased from 0.6% (1/168) in 2015 to 2.9% (4/140) in 2016, before dropping to 1.4% (2/144) in 2017 (Figure 7, Table 7, Table 8, Appendix C and Appendix D).

The proportion of pharyngeal isolates resistant to azithromycin among males increased to 3.9% (6/152) from 3.6% (4/111) in 2016 with no isolates resistant to azithromycin in 2015. Conversely, the proportion of pharyngeal isolates from females experienced a slight decrease throughout the three years (1.9% (1/52) in 2015; 1.8% (1/57) in 2016, and 1.7% (1/59) in 2017). There were no anogenital isolates resistant to azithromycin among females in 2015, however, in 2016, 6.3% (3/48) of cervical isolates were resistant to azithromycin, dropping to 2.6% (1/39) in 2017 (Figure 8, Table 8 and Appendix D). Males with anogenital isolates resistant to azithromycin saw a decrease in 2017 to 0.8% (4/475) from 1.2% (5/431) in 2016 and 0.4% (2/501) in 2015 (Figure 8, Table 8 and Appendix D).

Figure 7. Distribution of azithromycin resistance by sex or sexual behaviour, ESAG 2015-2017

figure 7

Text description

The bar chart presents the proportion of ESAG isolates with resistance to azithromycin by sex or sexual behaviour groupings. The horizontal axis represents the year while the vertical axis represents the resistance proportion.

Sex or Sexual Behaviour 2015 2016 2017
gbMSM male 0.3 2.8 2.3
Non-gbMSM male 0.5 0.0 0.7
Female 0.8 2.9 1.4
Overall 0.4 1.9 1.6

Figure 8. Distribution of azithromycin resistance by sex and infection site, ESAG 2015-2017

figure 8

Text description

The bar chart presents the proportion of ESAG isolates with resistance to azithromycin by sex and infection site groupings. The horizontal axis represents the year while the vertical axis represents the resistance proportion.

Sex or Sexual Behaviour and Infection Site 2015 2016 2017
Cervix 0.0 6.3 2.6
Urethra 0.6 1.0 0.8
Pharynx – Female 1.9 1.8 1.7
Pharynx – Male 0.0 3.6 3.9
Rectum – Female 0.0 0.0 0.0
Rectum – Male 0.0 1.5 0.9
Overall 0.4 1.9 1.6

The Canadian Guidelines on Sexually Transmitted InfectionsReference 1 recommend combination therapy with 250 mg ceftriaxone injected intramuscularly (IM) and azithromycin 1 g orally (PO) as a first-line treatment for uncomplicated anogenital and pharyngeal gonorrhea infections in adults. The guidelines also recommended combination therapy of 800 mg cefixime orally (PO) and azithromycin 1 g orally (PO) for other adults with anogenital infections. The Agency's National Microbiology Laboratory tests for resistance to these key antimicrobials as well as a standard panel of other antimicrobials. Results for these are below.

Ciprofloxacin

The prevalence of ciprofloxacin resistance was 30.1% (239/794) in 2015 increasing to 43.4% (297/684) in 2016, before dropping to 27.9% (215/771) in 2017. A large increase was seen in isolates obtained from females (13/1% in 2015 to 25.0% in 2017) and non-gbMSM (13.9% in 2015 to 24.7% in 2017), while the proportion of isolates from gbMSM males experienced a 34% decrease (46.5% to 31.3%) (Figure 9 and Appendix C).

Tetracycline

Nearly 60% of the isolates in 2015 and 2016 were resistant to tetracycline (477/794 in 2015 and 388/684 in 2016), decreasing to 42.5% (328/771) in 2017. A large increase was seen in isolates from females (44.0% in 2015, 53.6% in 2016 and 54.9% in 2017) (Figure 9 and Appendix C).

Penicillin

Roughly 15% of isolates from ESAG cases were resistant to penicillin in 2015 (120/794) and 2016 (102/684) in 2016, which decreased to 5.7% (44/771) in 2017. The only group which saw an increase was females which increased from 5.4% (9/168) in 2015 to 19.3% (27/140) in 2016, before decreasing to 6.9% (10/144) in 2017. The largest decrease was seen in isolates from gbMSM males, which saw steady decreases from 2015 to 2017 (21.5%, 13.5% and 5.2% respectively) (Figure 9 and Appendix C).

Erythromycin

Resistance to erythromycin remained fairly constant from 2015 to 2016 with 26.5% (211/794) of isolates exhibiting resistance in 2015 and 25.7% (176/684) in 2016. There was an almost 50% decrease in 2017 with 13.5% (104/771) of isolates exhibiting resistance to erythromycin. This decrease mostly came from isolates from gbMSM cases, where a decrease from 42.4% (168/396) in 2015 to 30.0% (98/327) in 2016 and 14.9% (52/348) in 2017 was seen (Figure 9 and Appendix C).

Spectinomycin

No resistance to spectinomycin was identified in any of the submitted isolates from 2015 to 2017 (Figure 9 and Appendix C).

Multidrug Resistance

In all years, isolates that had decreased susceptibility to cefixime and/or ceftriaxone were also resistant to one or more other antimicrobials; however, none of these isolates was resistant to azithromycin.

Figure 9. Decreased susceptibility and resistance proportions to selected antimicrobials by province/territory, ESAG 2015-2017

figure 9

Text description

The bar chart presents to proportion of ESAG isolates with decreased susceptibility or resistance to ciprofloxacin, tetracycline, penicillin, erythromycin and spectinomycin by province/territory. The horizontal axis represents the antimicrobial while the vertical axis represents the decreased susceptibility or resistance proportion.

Province/Territory Ciprofloxacin Tetracycline Penicillin Erythromycin Spectinomycin
Alberta 33.1 52.2 11.0 20.8 0.0
Manitoba 37.2 53.5 30.2 32.6 0.0
Nova Scotia 35.2 52.1 18.3 25.4 0.0
Northwest Territories 70.0 70.0 30.0 80.0 0.0
Overall 33.4 52.3 11.7 21.5 0.0
Table 7. Decreased susceptibility to cefixime and ceftriaxone and resistance to azithromycin by sex, sexual behaviour and province/territory, ESAG 2015-2017Table 7 Footnote a
Sex or Sexual Behaviour Alberta Manitoba Nova Scotia Northwest Territories Overall
CefiximeDS 2015 2016 2017 2015 2016 2017 2015 2016 2017 2015 2016 2017 2015 2016 2017
gbMSM Male 3 0 1 0 0 0 0 0 0 0 0 0 3 0 1
(0.8) (0.0) (0.3) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.8) (0.0) (0.3)
Non-gbMSM Male 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0
(0.5) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.4) (0.0) (0.0)
Female 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1
(0.0) (0.0) (0.8) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.7)
Male - Unknown 0 0 0 1 0 0 1 0 0 0 0 0 2 0 0
(0.0) (0.0) (0.0) (100.0) (0.0) (0.0) (33.3) (0.0) (0.0) (0.0) (0.0) (0.0) (33.3) (0.0) (0.0)
Total  4 0 2 1 0 0 1 0 0 0 0 0 6 0 2
(0.5) (0.0) (0.3) (6.7) (0.0) (0.0) (7.1) (0.0) (0.0) (0.0) (0.0) (0.0) (0.8) (0.0) (0.3)
CeftriaxoneDS 2015 2016 2017 2015 2016 2017 2015 2016 2017 2015 2016 2017 2015 2016 2017
gbMSM Male 11 2 2 0 0 0 0 0 0 0 0 0 11 2 2
(2.9) (0.7) (0.6) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (2.8) (0.6) (0.6)
Non-gbMSM Male 0 1 0 1 0 0 0 0 0 0 0 0 1 1 0
(0.0) (0.5) (0.0) (16.7) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.4) (0.5) (0.0)
Female 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0
(0.0) (0.8) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.7) (0.0)
Male - Unknown 0 0 1 1 0 0 1 0 0 0 0 0 2 0 1
(0.0) (0.0) (50.0) (100.0) (0.0) (0.0) (33.3) (0.0) (0.0) (0.0) (0.0) (0.0) (33.3) (0.0) (12.5)
Total 11 4 3 2 0 0 1 0 0 0 0 0 14 4 3
(1.4) (0.6) (0.4) (13.3) (0.0) (0.0) (7.1) (0.0) (0.0) (0.0) (0.0) (0.0) (1.8) (0.6) (0.4)
AzithromycinR 2015 2016 2017 2015 2016 2017 2015 2016 2017 2015 2016 2017 2015 2016 2017
gbMSM Male 1 7 8 0 0 0 0 2 0 0 0 0 1 9 8
(0.3) (2.4) (2.4) (0.0) (0.0) (0.0) (0.0) (11.8) (0.0) (0.0) (0.0) (0.0) (0.3) (2.8) (2.3)
Non-gbMSM Male 1 0 2 0 0 0 0 0 0 0 0 0 1 0 2
(0.5) (0.0) (0.8) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.4) (0.0) (0.7)
Female 1 3 2 0 0 0 0 1 0 0 0 0 1 4 2
(0.6) (2.4) (1.5) (0.0) (0.0) (0.0) (0.0) (12.5) (0.0) (0.0) (0.0) (0.0) (0.6) (2.9) (1.4)
Male - Unknown 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
(0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0)
Total 3 10 12 0 0 0 0 3 0 0 0 0 3 13 12
(0.4) (1.6) (1.6) (0.0) (0.0) (0.0) (0.0) (10.7) (0.0) (0.0) (0.0) (0.0) (0.4) (1.9) (1.6)
See Table 2 for denominators. R/DS: Resistance or Decreased Susceptibility.
Table 7 Footnote a

Includes duplicates.

Table 7 Return to footnote a referrer

Table 8. Decreased susceptibility to cefixime, ceftriaxone, or resistance to azithromycin by sex or sexual behaviour, ESAG 2015-2017Table 8 Footnote a
Sex or Sexual Behaviour 2015 2016 2017
N % N % N %
CefiximeDS
gbMSM Male 3 0.8 0 0.0 1 0.3
Non-gbMSM Male 1 0.4 0 0.0 0 0.0
Female 0 0.0 0 0.0 1 0.7
Male - Unknown 2 33.3 0 0.0 0 0.0
Total 6 0.8 0 0.0 2 0.3
CeftriaxoneDS
gbMSM Male 11 2.8 2 0.6 2 0.6
Non-gbMSM Male 1 0.4 1 0.5 0 0.0
Female 0 0.0 1 0.7 0 0.0
Male - Unknown 2 33.3 0 0.0 1 12.5
Total 14 1.8 4 0.6 3 0.4
AzithromycinR
gbMSM Male 1 0.3 9 2.8 8 2.3
Non-gbMSM Male 1 0.4 0 0.0 2 0.7
Female 1 0.6 4 2.9 2 1.4
Male - Unknown 0 0.0 0 0.0 0 0.0
Total 3 0.4 13 1.9 12 1.6
See Table 2 for denominators. R/DS: Resistance or Decreased Susceptibility.
Table 8 Footnote a

Includes duplicates.

Table 8 Return to footnote a referrer

Figure 10. Decreased susceptibility to cefixime, ceftriaxone, or resistance to azithromycin by sex or sexual behaviour, ESAG 2015-2017

figure 10

* DS:  Decreased Susceptibility; R:  Resistance

Text description

The bar chart presents the proportion of decreased susceptibility to cefixime or ceftriaxone or resistance to azithromycin by sex or sexual behaviour groupings and year. The horizontal axis represents the year and antimicrobial while the vertical axis represents the decreased susceptibility or resistance proportion.

Year and Sex or Sexual Behaviour Cefixime Ceftriaxone Azithromycin
2015 gbMSM male 0.9 3.4 0.3
Non-gbMSM male 0.5 0.5 0.5
Female 0.0 0.0 0.8
2016 gbMSM male 0.0 0.6 2.8
Non-gbMSM male 0.0 0.5 0.0
Female 0.0 0.7 2.9
2017 gbMSM male 0.3 0.6 2.3
Non-gbMSM male 0.0 0.0 0.7
Female 0.7 0.0 1.4

Sequence Typing

NG-MAST sequencing of 2,120 isolates identified 303 different sequence types (STs). The 20 most prevalent STs in 2015, 2016, and 2017 are represented in Figure 11. In 2015, ST7638 (23.0%, 11/483) was the most prevalent ST followed by ST11299 (9.5%, 46/483) and ST5985 (7.0%, 34/483). In 2016, ST7638 (11.4%, 31/533) was the most prevalent ST, followed by ST10451 (8.3%, 44/533) and ST11299 (6.8%, 36/533). In 2017, ST5985 (22.4%, 85/379) was the most prevalent ST, followed by ST10451 (7.4%, 28/379) and ST5441 (6.6%, 25/379). The three most prevalent sequence types from 2015 to 2017 combined were ST7638 at 12.5% (175/1395), ST5985 at 10.8% (150/1395) and ST11299 at 6.2% (86/1395). Figure 12 represents the genetic relationship between 20 of the most prevalent STs using the Maximum Likelihood method.

  • ST7638 (N=175) was identified in 111 isolates in 2015, 61 isolates in 2016, and three isolates in 2017 and is primarily found in the non-gbMSM male population (N=152). The majority of isolates with this ST had low-level tetracycline resistance.
  • ST5985 (N=150) was identified in 34 isolates in 2015, 31 isolates in 2016, and increased more than two-fold in 2017 to 85 isolates. Although 70% of ST5985 isolates were from non-gbMSM males, it was the primary ST identified among gbMSM males. TRNG was the predominant AMR of the isolates with this ST.
  • ST11299 (N=86) and ST2318 (N=40) were identified in all three years. ST11299 was identified in 46 isolates in 2015 (9.5%), 36 isolates in 2016 (6.8%) and four isolates in 2017 (1.1%). ST2318 was identified in 13 isolates in 2015 (2.7%), 25 isolates in 2016 (4.7%), and two isolates in 2017 (0.5%) (Figure 11). This cluster was highest in the gbMSM population and resistant to ciprofloxacin, tetracycline, penicillin and erythromycin. A small number also showed decreased susceptibility to cephalosporins.
  • ST10451 (N=81) was identified in nine isolates in 2015, 44 isolates in 2016 and decreased to 28 isolates in 2017. This ST was identified primarily in the non-gbMSM population. All of these isolates were resistant to ciprofloxacin and the majority (N=75) were also resistant to tetracycline. In addition, there was a high proportion (72.8% N=59) that were resistant to erythromycin, and over a third were resistant to penicillin (39.5% N=32). A small number of isolates were resistant to azithromycin (N=3) and one showed decreased susceptibility to cephalosporins.
  • ST12302 (N=18) was identified in eight isolates in 2016 and ten isolates in 2017. This ST was found primarily in gbMSM males and these isolates were equally resistant to ciprofloxacin (N=18), erythromycin (N=18) and tetracycline (N=18). Half of the isolates with this ST were resistant to azithromycin (N=9). ST123020 has been identified in large numbers in central Canada since 2013. In 2013, it was the most prevalent ST across Canada at 24.1% (688/2,853)Reference 25.

Figure 11. Proportion of isolates for the top 20 NG-MAST sequence types in N. gonorrhoeae isolates, ESAG 2015-2017

figure 11

Text description

This bar chart presents the proportion of isolates for the 20 most frequent isolates that were tested using NG-MAST method.  The horizontal axis represents the different sequence types while the vertical axis shows the proportion of isolates.

Sequence Type 2015 2016 2017
ST-7638 23.0 11.4 0.8
ST-5985 7.0 5.8 22.4
ST-11299 9.5 6.8 1.1
ST-10451 1.9 8.3 7.4
ST-9663 6.8 3.4 0.0
ST-5441 0.6 2.6 6.6
ST-2318 2.7 4.7 0.5
ST-10532 3.3 3.4 0.3
ST-2400 2.5 0.8 3.4
ST-8890 0.2 0.0 5.5
ST-11086 1.0 2.1 1.1
ST-4709 0.6 2.8 0.3
ST-12302 0.0 1.5 2.6
ST-14788 0.0 1.3 2.9
ST-9999 0.6 2.8 0.0
ST-6793 0.0 2.6 0.8
ST-5624 0.2 0.6 3.4
ST-16099 0.0 0.0 4.5
ST-12122 1.9 1.1 0.0
ST-5785 0.4 1.7 0.3

Figure 12. Genetic relationship of prevalent NG-MAST sequence types in N. gonorrhoeae, ESAG 2015-2017

figure 12

† non-gbMSM includes females in this figure.

Text description

This dendrogram shows the genetic relationship between 20 of the most prevalent sequence types using the maximum likelihood method.  The left-most section of the figure shows the phylogenetic relationships and relatedness of each ST - the branch length of the tree represents the number of base pair substitutions per site. The corresponding table on the right shows the NG-MAST (STs) in the rows, and the number of each ST, the year, the sex/sexual behaviour, and the resistance characterization (CipR, CephDS, AzR, TRNG, PPNG, PenR, TetR, EryR) as the column labels. Each variable for the column is coloured and the presence of the variable corresponds to the matching colour present in the NG-MAST row.

ST-7638
This ST was identified in 175 isolates (111 in 2015, 61 in 2016 and 3 in 2017), is primarily found in non-gbMSM males and the majority of isolates with the ST show low-level tetracycline resistance
ST-5985
This ST, identified in all three years, is the primary ST identified among gbMSM males, and has high level resistance to tetracycline (TRNG)
ST-11299 ST-2318
This cluster is found primarily in gbMSM, is multi-drug resistant and a small number also shows decreased susceptibility to cephalosporins as well.
ST-12302
This ST was identified in 8 isolates in 2016 and 10 isolates in 2017 with no isolates in 2015. This ST is primarily found in gbMSM males and were equally resistant to ciprofloxacin, erythromycin and tetracycline. It has been identified in large numbers in central Canada since 2013.

Treatment

Treatment information was available for 99.7% (N=666), 96.8% (N=662), and 97.5% (N=749) of the gonorrhea cases in 2015, 2016, and 2017, respectively. Adherence to the treatment recommended in the Canadian Guidelines on Sexually Transmitted InfectionsReference 1 (Table 9) was above 85% for all treatment groups, except for other adultsFootnote e with pharyngeal infections. In this category, 19.6% of cases received a preferred treatment in 2015; this proportion rose to 23.3% in 2016 and 36.1% in 2017, an 84% increase. More than half of these cases received the alternative therapy recommended, 57.1% in 2015, 63.3% in 2016, and 50.8% in 2017 (Table 10, Table 11, Figure 13 and Appendix E).

Ninety-one percent of anogenital infections among other adults were treated with preferred therapies in all years (Table 10, Table 11, Figure 13 and Appendix E). The preferred combination therapy of cefixime and azithromycin was prescribed more frequently than the preferred combination therapy of ceftriaxone and azithromycin for anogenital infections among other adults in all years (81.9% vs 9.1% in 2015; 86.8% vs. 4.3% in 2016; and 88.0% vs. 2.9% in 2017) representing an overall decrease of 68% in prescribing the preferred therapy for other adults between 2015 to 2017 (Table 10, Table 11 and Appendix E).

Despite an 84% increase in the prescribing of the preferred combination therapy of ceftriaxone and azithromycin from 2015 to 2017 (19.6% in 2015, 23.3% in 2016, and 36.1% in 2017), nearly half of other adults with pharyngeal infections were prescribed the alternate combination therapy of cefixime and azithromycin in all years (51.8% in 2015, 51.7% in 2016, and 47.5% in 2017) (Table 10, Table 11 and Appendix E).

Table 9. Canadian Treatment Guidelines for Neisseria gonorrhoeaeReference 1
Treatment gbMSM Males Other AdultsTable 9 Footnote b
AnogenitalTable 9 Footnote a Infections Preferred Therapy Ceftriaxone 250 mg + Azithromycin 1 g Ceftriaxone 250 mg + Azithromycin 1 g
n/a Cefixime 800 mg + Azithromycin 1g
Alternative Therapy Cefixime 800 mg + Azithromycin 1 g
OR
Azithromycin 2 g
OR
SpectinomycinTable 9 Footnote c 2 g + Azithromycin 1 g
SpectinomycinTable 9 Footnote c 2 g + Azithromycin 1 g
OR
Azithromycin 2 g
Pharyngeal Infections Preferred Therapy Ceftriaxone 250 mg + Azithromycin 1 g Ceftriaxone 250 mg + Azithromycin 1 g
Alternative Therapy Cefixime 800 mg + Azithromycin 1 g Cefixime 800 mg + Azithromycin 1g
OR
Azithromycin 2 g
Table 9 Footnote a

Anogenital infections include genital and rectal infections.

Table 9 Return to footnote a referrer

Table 9 Footnote b

Other Adults include non-gbMSM males, females and transgendered. It does not include males with unknown sexual behavior or unknown sex.

Table 9 Return to footnote b referrer

Table 9 Footnote c

Spectinomycin is available only through SAP.

Table 9 Return to footnote c referrer

Table 10. Prescribed treatment for culture cases, ESAG 20015-2017
  2015 2016 2017
N % N % N %
AnogenitalTable 10 Footnote c gbMSM Male
Preferred Ceftriaxone 250 mg + Azithromycin 1 g 175 87.5 182 82.7 161 80.9
Alternative Cefixime 800 mg + Azithromycin 1 g 10 5.0 8 3.6 6 3.0
Azithromycin 2 g 6 3.0 12 5.5 10 5.0
Spectinomycin 2 g + Azithromycin 1 g 0 0.0 0 0.0 0 0.0
Other combination therapyTable 10 Footnote a 6 3.0 16 7.3 22 11.1
Other monotherapyTable 10 Footnote b 2 1.0 2 0.9 0 0.0
Unknown 1 0.5 0 0.0 0 0.0
Total 200 220 199
Other AdultsTable 10 Footnote d
Preferred Ceftriaxone 250 mg + Azithromycin 1 g 26 9.1 12 4.3 10 2.9
Cefixime 800 mg + Azithromycin 1 g 235 81.9 243 86.8 302 88.0
Alternative Spectinomycin 2 g + Azithromycin 1 g 0 0.0 0 0.0 0 0.0
Azithromycin 2 g 7 2.4 11 3.9 10 2.9
Other combination therapyTable 10 Footnote a 14 4.9 8 2.9 20 5.8
Other monotherapyTable 10 Footnote b 4 1.4 6 2.1 1 0.3
Unknown 1 0.3 0 0.0 0 0.0
Total 287 280 343
Pharyngeal gbMSM Male
Preferred Ceftriaxone 250 mg + Azithromycin 1 g 108 90.8 84 83.2 124 85.5
Alternative Cefixime 800 mg + Azithromycin 1 g 2 1.7 5 5.0 4 2.8
Other combination therapyTable 10 Footnote a 6 5.0 9 8.9 14 9.7
Other monotherapyTable 10 Footnote b 3 2.5 3 3.0 3 2.1
Unknown 0 0.0 0 0.0 0 0.0
Total 119 101 145
Other AdultsTable 10 Footnote d
Preferred Ceftriaxone 250 mg + Azithromycin 1 g 11 19.6 14 23.3 22 36.1
Alternative Cefixime 800 mg + Azithromycin 1 g 29 51.8 31 51.7 29 47.5
Azithromycin 2 g 3 5.4 7 11.7 2 3.3
Other combination therapyTable 10 Footnote a 8 14.3 4 6.7 8 13.1
Other monotherapyTable 10 Footnote b 2 3.6 4 6.7 0 0.0
Unknown 3 5.4 0 0.0 0 0.0
Total 56 60 61
Table 10 Footnote a

Other combination therapy consists of combinations other than the preferred or alternative therapies recommended in the Canadian Guidelines on Sexually Transmitted Infections1, or the preferred/alternative treatments where dosage information was not available.

Table 10 Return to footnote a referrer

Table 10 Footnote b

Other monotherapy consists of single drug therapies, excluding azithromycin 2 g which is considered an alternative treatment.

Table 10 Return to footnote b referrer

Table 10 Footnote c

Anogenital infections include genital and rectal infections.

Table 10 Return to footnote c referrer

Table 10 Footnote d

Other Adults include non-gbMSM males, females and transgendered. It does not include males with unknown sexual behavior or unknown sex.

Table 10 Return to footnote d referrer

Figure 13. Adherence to Canadian treatment guidelinesReference 1 for gbMSM males and other adults*

figure 13

*Other Adults include non-gbMSM males, females and transgendered. It does not include males with unknown sexual behavior or unknown sex.
** Anogenital infections include genital and rectal infections.

Text description

This stacked bar graph displays the percentage of gbMSM and other adults with either anogenital or pharyngeal infections that were treated with the preferred, alternative, other combination and other monotherapy according to Canadian Treatment Guidelines. The horizontal axis represents the percent adherence to the treatment guidelines and the vertical axis represents the infection type (anogenital or pharyngeal) in gbMSM and other adults grouped by year.

Treatment Anogenital gbMSM Anogenital Other Adults Pharyngeal gbMSM Pharyngeal Other Adults
2015 2016 2017 2015 2016 2017 2015 2016 2017 2015 2016 2017
Preferred 87.5 82.7 80.9 90.9 91.1 91.0 90.8 83.2 85.5 19.6 23.3 36.1
Alternative 8.0 9.1 8.0 2.4 3.9 2.9 1.7 5.0 2.8 57.1 63.3 50.8
Other Combination 3.0 7.3 11.1 4.9 2.9 5.8 5.0 8.9 9.7 14.3 6.7 13.1
Other Monotherapy 1.0 0.9 0.0 1.4 2.1 0.3 2.5 3.0 2.1 3.6 6.7 0.0
Unknown 0.5 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 5.4 0.0 0.0
Table 11. Most prescribed treatments by treatment category, ESAG 2015-2017
Treatment 2015Table 11 Footnote a 2016Table 11 Footnote b 2017Table 11 Footnote c
N % N % N %
AnogenitalTable 11 Footnote d gbMSM Males (P) Ceftriaxone 250 mg, Azithromycin 1 g 175 87.5 182 82.7 161 80.9
(A) Azithromycin 2 g 6 3.0 12 5.5 10 5.0
(A) Cefixime 800 mg, Azithromycin 1 g 10 5.0 8 3.6 6 3.0
(N) Ceftriaxone 250 mg, Doxycycline 100 mg 0 0.0 13 5.9 14 7.0
(N) Other 9 4.5 5 2.3 8 4.0
Total 200 220 199
Other AdultsTable 11 Footnote e (P) Cefixime 800 mg, Azithromycin 1 g 235 81.9 243 86.8 302 88.0
(P) Ceftriaxone 250 mg, Azithromycin 1 g 26 9.1 12 4.3 10 2.9
(A) Azithromycin 2 g 7 2.4 11 3.9 10 2.9
(N) Ceftriaxone 250 mg, Cefixime 800 mg, Azithromycin 1 g 6 2.1 0 0.0 0 0.0
(N) Other 13 4.5 14 5.0 21 6.1
Total 287 280 343
Pharyngeal gbMSM Males (P) Ceftriaxone 250 mg, Azithromycin 1 g 108 90.8 84 83.2 124 85.5
(A) Cefixime 800 mg, Azithromycin 1 g 2 1.7 5 5.0 4 2.8
(N) Ceftriaxone 250 mg, Doxycycline 100 mg 1 0.8 5 5.0 7 4.8
(N) Azithromycin 2 g 3 2.5 2 2.0 3 2.1
(N) Other 5 4.2 5 5.0 7 4.8
Total 119 101 145
Other AdultsTable 11 Footnote e (P) Ceftriaxone 250 mg, Azithromycin 1 g 11 19.6 14 23.3 22 36.1
(A) Cefixime 800 mg, Azithromycin 1 g 29 51.8 31 51.7 29 47.5
(A) Azithromycin 2 g 3 5.4 7 11.7 2 3.3
(N) Ceftriaxone 250 mg, Doxycycline 100 mg 0 0.0 2 3.3 4 6.6
(N) Other 13 23.2 6 10.0 4 6.6
Total 56 60 61
  • (P) Preferred treatment in the  – Gonococcal Infections Chapter, Revised July 2013 (treatment guidelines)1.
  • (A) Alternative treatment in the treatment guidelines.
  • (N) Not recommended in the treatment guidelines.
Table 11 Footnote a

In 2015, there were six males with unknown sexual behavior, who are excluded from this table.

Table 11 Return to footnote a referrer

Table 11 Footnote b

In 2016, there were three males with unknown sexual behavior and one person with unknown sex or sexual behavior, who were excluded from this table.

Table 11 Return to footnote b referrer

Table 11 Footnote c

In 2017, there were eight males with unknown sexual behavior who were excluded from this table.

Table 11 Return to footnote c referrer

Table 11 Footnote d

Anogenital infections include genital and rectal infections.

Table 11 Return to footnote d referrer

Table 11 Footnote e

Other Adults include non-gbMSM males, females and transgender. It does not include males with unknown sexual behavior or unknown sex.

Table 11 Return to footnote e referrer

From 2015-2017, nearly 7% (101/1529) of anogenital infections and 12% (64/542) of pharyngeal infections were prescribed treatments that were either “other combination” or “other monotherapies” not recommended in the Canadian Guidelines on Sexually Transmitted InfectionsReference 1. The proportion of cases who were prescribed either the preferred or alternative treatments with an extra antibiotic or increased dosage was 32.1% (53/165) and 67.9% (112/165) of the cases were prescribed a treatment that was not part of the guidelines. These plus an additional five treatments that were “unknown” results in 5.6% (117/2071) of all treatments that were not part of the treatment guidelines (Table 12).

Table 12. Other combination or monotherapy, ESAG 2015-2017 (N=165)
Treatment Anogenital Pharyngeal
gbMSM Males Other Adults gbMSM Males Other Adults
N % N % N % N %
Preferred plusTable 12 Footnote a 13 2.1 16 1.8 5 1.4 8 4.5
Alternative plusTable 12 Footnote a 0 0.0 1 0.1 0 0.0 1 0.6
Preferred but higher dosage 0 0.0 1 0.1 1 0.3 1 0.6
Preferred but higher dosage plusTable 12 Footnote a 0 0.0 1 0.1 2 0.5 0 0.0
Alternative but higher dosage 0 0.0 2 0.2 1 0.3 0 0.0
Preferred but lower dosage 1 0.2 1 0.1 1 0.3 0 0.0
Alternative but lower dosage 1 0.2 0 0.0 0 0.0 0 0.0
Only 1 of 2 preferred or alternative antibiotics 1 0.2 8 0.9 0 0.0 3 1.7
Only 1 of 2 preferred or alternative antibiotics plusTable 12 Footnote a 29 4.7 18 2.0 16 4.4 9 5.1
Not recommended 3 0.5 5 0.5 12 3.3 4 2.3
Unknown 1 0.2 1 0.1 0 0.0 3 1.7
Total Other Combination or MonotherapyTable 12 Footnote b 48 7.8 53 5.8 38 10.4 29 16.4
Table 12 Footnote a

Plus antibiotics include:  Doxycycline 100 mg, Spectinomycin 2 g, Ciprofloxacin 500 mg, Bicillin and Metronidazole.

Table 12 Return to footnote a referrer

Table 12 Footnote b

See Table 10 for denominators.

Table 12 Return to footnote b referrer

Treatment Failure

From 2015 to 2017, there were less than 1% of cases reporting treatment failure (0 in 2015, 0.4% (3/684)) in 2016 and 0.3% in 2017 (2/768).  All of the cases of treatment failure in 2016 were from Manitoba (n=3) and all of the 2017 cases were from Alberta (n=2).

Discussion

This is the third ESAG report that summarizes gonococcal resistance and susceptibility data and describes the public health implications of emerging resistance to cephalosporins and azithromycin.

As a result of the ESAG initiative, partner laboratories submitted increased numbers of gonorrhea isolates to enable improved analysis and information. In 2013, there were 124 cultures from the two sites that were part of ESAGReference 37. In 2014, these same two sites submitted 534 cultures and two new sites began participating; 786 cultures were captured from four jurisdictions in 2015Reference 38. In 2019, a fifth jurisdiction submitted retrospective data for the 2015-2017 time period. The likelihood that these cultures could have been captured by routine laboratory surveillance by the NML cannot be ruled out; however, ESAG allows for the capturing of additional epidemiological information to better understand treatments, populations, and risk factors associated with gonorrheal infections.

Over 80% of cases captured in ESAG were male. This is consistent with historical data, which show that in 2017, 65% (18,734/29,034) of reported gonorrhea cases in Canada were among malesReference 5Reference 6Reference 31. This can also suggest that males, especially gay, bisexual and other men who have sex with men (gbMSM) are overrepresented in ESAG because gbMSM males are more likely to be asked for a specimen for culture in accordance with the recommendations from the Canadian Guidelines on Sexually Transmitted InfectionsReference 1.

More than half of ESAG cases who provided specimens for culture sought care due to signs and/or symptoms, which is consistent with the Canadian Guidelines on Sexually Transmitted InfectionsReference 1 recommendation for obtaining cultures from symptomatic gbMSM and non-gbMSM. However, among gbMSM, approximately one-quarter reported STI screening or being a case contact as the reason for visit. The most common reason for females seeking treatment was the presence of symptoms.

Treatment data from ESAG indicate that the single preferred treatment for treating both anogenital and pharyngeal infections in gbMSM (ceftriaxone (250 mg) and azithromycin (1 g) therapy) has remained the most prevalent treatment for these cases. However, this combination therapy has decreased in use for treating non-gbMSM (including females) from 9.1% in 2015, to 4.3% in 2016 and 2.9% in 2017 for anogenital infections and increased from 19.6% in 2015, to 23.3% in 2016 to 36.1% in 2017 for pharyngeal infections. For anogenital infections in non-gbMSM, this is not a problem as the second preferred therapy of cefixime (800 mg) and azithromycin (1g) has increased by 8% from 2015 to 2017 (81.9% in 2015, 86.8% in 2016 and 88.0% in 2017). There may be cause for concern, however, that pharyngeal infections in non-gbMSM (including females) were treated with alternate therapy (either cefixime 800 mg and azithromycin 1 g or a single dose of azithromycin 2 g) in more than half of the cases (57.1% in 2015, 63.3% in 2016 and 50.8% in 2017), with other therapies being used 13.1%. This may be the result of pharyngeal infections often being asymptomatic; with the clinician only finding a positive result after the treatment was prescribed for an anogenital infection or other co-infection(s) for which data is not collected for this surveillance program.

The majority of cases at the five participating jurisdictions were prescribed either preferred or alternative therapies as currently proposed by the Canadian Guidelines on Sexually Transmitted InfectionsReference 1. This high degree of consistency is likely the result of familiarity on the clinicians at STI clinics with the Canadian Guidelines on Sexually Transmitted Infections and may not necessarily be indicative of general practitioners' prescribing behaviours. As well, since co-infection and contraindication data is not always provided for the ESAG cases, it is difficult to determine the reasoning behind other combination or monotherapies being prescribed. Some cases may require the use of medications outside of the recommendations of the Canadian Guidelines on Sexually Transmitted Infections to treat these cases.

Limitations

Results from ESAG are not representative of all gonorrhea cases or culture-confirmed gonorrhea cases in Canada. Similarly, sentinel sites may not be representative of their jurisdictions. In addition to limited geographic representation, ESAG cases may have been over-represented by gbMSM. Because the majority of cases in ESAG were from Alberta, any aggregated results should be interpreted with caution. Moreover, the small number of ESAG cases in Winnipeg, Halifax and the Northwest Territories made some data difficult to interpret.

The relative representativeness of gbMSM, non-gbMSM and females may vary across these sub-populations. This variation may be associated with proportion of participation per sub-population and profile of those who visited the ESAG sites. For example, the participating gbMSM could represent all gbMSM cases from these jurisdictions in terms of behaviours, while the participating females and non-gbMSM could be more at risk compared to their source sub-populations.

The proportion of infection sites of the different sexes and behaviour groups may be biased according to the screening guidelines of each sentinel site or provincial jurisdiction. The low number of isolates with decreased susceptibility to cephalosporins and resistance to azithromycin made it difficult to determine significant increases and decreases between 2015 and 2017 or significant differences between isolates from different infection sites, sexes and sexual behaviours.

The collection of preferred and alternate treatment data from sentinel sites reflected the prescribing practices in the participating STI clinics and was not expected to reflect gonorrhea treatment practices in non-participating STI clinics in all four provincial jurisdictions where the majority of gonorrhea cases were diagnosed in 2015 to 2017. Also, provincial treatment guidelines and availability of preferred antimicrobials may influence chosen therapies; a client may have had other empiric therapies based on risks or presentations during an initial visit, prior to being diagnosed with gonorrhea.

The completion rate of some variables was low and/or limited to certain sentinel sites and this is another reason these results would not likely reflect the overall Canadian context. In addition, some of the variables rely of self-reported data, which may not be accurate and could result in under- or over-reporting.

All of the isolates from ESAG cases were from swabs taken during initial visits or call-backs after a positive nucleic acid amplification test (NAAT) from the initial visit. There were five cases of treatment failure and seven cases of possible treatment failure reported during the study period. Because detailed clinical information, such as allergies, other infections or contraindications, was not collected for ESAG, it was not possible to definitively determine why the preferred or alternative was not prescribed. Tests of cure and treatment failures can be difficult to measure using surveillance data because they rely on the ability to detect negative results.

Conclusion

The Enhanced Surveillance of Antimicrobial-Resistant Gonorrhea (ESAG) initiative monitored N. gonorrhoeae antimicrobial susceptibility from 2015 to 2017 in participating jurisdictions and provided additional information to supplement the laboratory-based passive surveillance of antimicrobial-resistant gonorrhea. The ESAG data for 2015 to 2017 demonstrated decreased susceptibility to antimicrobials recommended for preferred therapy such as ceftriaxone, cefixime, and resistance to azithromycin. This suggests that decreased susceptibility or resistance to these antimicrobials could complicate gonorrhea treatment substantially in the future.

The ESAG initiative provides useful integrated epidemiological and laboratory data describing the sexual partnering, clinical information, and antimicrobial susceptibility rates of gonococcal disease that would have otherwise not been available nationally. This project determined that it is possible to conduct surveillance of gonorrhea resistance at sentinel sites across Canada by integrating existing local/ provincial/ territorial surveillance. However, the number of sites able to collect such data remains limited and the expansion of ESAG's scope nationally remains a priority.

As Canada deals with increasing numbers of gonorrhea cases and the continued evolution, emergence and spread of antimicrobial resistance, efforts are ongoing to recruit additional ESAG sites to allow the collection of more representative data, which in turn would be more useful for informing treatment guidelines, clinical practice, and public health interventions. The ESAG program has allowed the monitoring of gonococcal antimicrobial susceptibility despite the decreasing use of culture in clinical practice for gonorrhea diagnosis and antimicrobial susceptibility testing. The recent reports of a N. gonorrhoeae strain resistant to ceftriaxone in Quebec and Alberta, Canada, poses a potential threat to the combination therapy currently being used to treat gonorrhea in CanadaReference 29. The continuous monitoring of antimicrobial resistance patterns via surveillance is of paramount importance to ensure the effectiveness of the recommended antimicrobials to treat gonococcal infection. The ESAG program can play an important role in assessing and monitoring the effectiveness of gonococcal treatment options and for the success of Canadian initiatives to combat AMR.

References

Reference 1

Public Health Agency of Canada. Canadian guidelines on sexually transmitted infections, gonococcal infections: Revised July 2013. https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines.html. 2013.

Return to reference 1

Reference 2

World Health Organization. Report on global sexually transmitted infection surveillance, 2018. 2018.

Return to reference 2

Reference 3

World Health Organization. Scientists warn that antibiotic-resistant gonorrhoea is on the rise. www.who.int/reproductivehealth/topics/rtis/amr-gonorrhoea-on-the-rise/en/. Accessed 12/18, 2018.

Return to reference 3

Reference 4

Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013.

Return to reference 4

Reference 5

Public Health Agency of Canada. Notifiable diseases on-line. Notifiable Diseases On-Line Web site. http://diseases.canada.ca/notifiable/. 2019.

Return to reference 5

Reference 6

Public Health Agency of Canada. Update on sexually transmitted infections in Canada, 2017. 2019.

Return to reference 6

Reference 7

World Health Organization. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. 2012.

Return to reference 7

Reference 8

Barry PM, Klausner JD. The use of cephalosporins for gonorrhea: The impending problem of resistance. Expert Opin Pharmacother. 2009;10(4):555-577.

Return to reference 8

Reference 9

Public Health Agency of Canada. National surveillance of antimicrobial susceptibilities of Neisseria gonorrhoeae in Canada:  Annual summary 2017. 2019.

Return to reference 9

Reference 10

World Health Organization. WHO guidelines for the treatment of Neisseria gonorrhoeae. 2016.

Return to reference 10

Reference 11

Tapsall J, Ndowa F, Lewis D, Unemo M. Meeting the public heatlh challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther. 2009;7(7):821-834.

Return to reference 11

Reference 12

Speers D. Gonococcal antimicrobial resistance:  80 years in the making. Microbiol Aust. 2019;40(2):57-62.

Return to reference 12

Reference 13

Public Health Agency of Canada. National surveillance of antimicrobial susceptibilities of Neisseria gonorrhoeae:  Annual summary 2016. 2017.

Return to reference 13

Reference 14

Bodie M, Gale-Rowe M, Alexandre S, Auguste U, Tomas K, Martin I. Addressing the rising rates of gonorrhea and drug-resistant gonorrhea:  there is no time like the present. CCDR. 2019;45(2/3):54-62.

Return to reference 14

Reference 15

Kirkcaldy R, Harvey A, Papp J, et al. Neisseria gonorrhoeae antimicrobial susceptibility surveillance - the Gonococcal Isolate Surveillance Project, 27 sites, United States, 2014. MMWR Surveill Summ. 2016;65(SS-7):1-19.

Return to reference 15

Reference 16

Wi T, Lahra M, Ndowa F, et al. Antimicrobial resistance in Neisseria gonorhoeae:  Global surveillance and a call for international collaborative action. PLOS Medicine. 2017;14(7):e1002344.

Return to reference 16

Reference 17

Martin I, Sawatzky P, Allen V, et al. Multidrug-resistant and extensively drug-resistant Neisseria gonorrhoeae in Canada, 2012-2016. CCDR. 2019;45(2/3):53.

Return to reference 17

Reference 18

Unemo M, Jensen J. Antimicrobial-resistant sexually transmitted infections:  gonorrhoeae and Mycoplasma genitalium. Nat Rev Urol. 2017;14(3):139-152.

Return to reference 18

Reference 19

Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA - Journal of the American Medical Association. 2013;309(2):163-170.

Return to reference 19

Reference 20

Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: Past, evolution, and future. Clin Microbiol Rev. 2014;27(3):587-613.

Return to reference 20

Reference 21

Public Health Agency of Canada. 2017-18 Departmental Plan. 2017. https://www.canada.ca/content/dam/phac-aspc/documents/corporate/transparency/corporate-management-reporting/reports-plans-priorities/2017-2018-report-plans-priorities-eng.pdf.

Return to reference 21

Reference 22

Public Health Agency of Canada. 2018-19 Departmental Plan. 2018. https://www.canada.ca/en/public-health/corporate/transparency/corporate-management-reporting/reports-plans-priorities/2018-2019-report-plans-priorities.html.

Return to reference 22

Reference 23

Public Health Agency of Canada. 2019-20 Departmental Plan. 2019. https://www.canada.ca/en/public-health/corporate/transparency/corporate-management-reporting/reports-plans-priorities/2019-2020-report-plans-priorities.html.

Return to reference 23

Reference 24

House of Commons, Standing Committee on Health (HESA). A study on the status of antimicrobial resistance in Canada and related recommendations. 2018.

Return to reference 24

Reference 25

Public Health Agency of Canada. Canadian Antimicrobial Resistance Surveillance System 2017 report. 2017. https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/drugs-health-products/canadian-antimicrobial-resistance-surveillance-system-2017-report-executive-summary/CARSS-Report-2017-En.pdf.

Return to reference 25

Reference 26

Public Health Agency of Canada. Canadian Antimicrobial Resistance Surveillance System - update 2018:  Executive summary. 2018.

Return to reference 26

Reference 27

Public Health Agency of Canada. A pan-canadian framework for action:  reducing the health impact of sexually transmitted and blood-borne infections in Canada by 2030. 2018. https://www.canada.ca/content/dam/phac-aspc/documents/services/infectious-diseases/sexual-health-sexually-transmitted-infections/reports-publications/sexually-transmitted-blood-borne-infections-action-framework/sexually-transmitted-blood-borne-infections-action-framework.pdf.

Return to reference 27

Reference 28

Lahra M, Martin I, Demczuk W, et al. Cooperative recognition of internationally disseminated ceftriaxone-resistant Neisseria gonorrhoeae strain. Emerging Infectious Disease. 2018;24(4):735-743.

Return to reference 28

Reference 29

Lefebvre B, Martin I, Demczuk W, et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Canada, 2017. Emerging Infectious Diseases. 2018;24(2):381-383.

Return to reference 29

Reference 30

Berenger B, Demczuk W, Gratrix J, Pabbaraju K, Smyczek P, Martin I. Genetic characterization and enhanced surveillance of ceftriaxone-resistant Neisseria gonorrhoeae strain, Alberta, Canada, 2018. Emerging Infectious Disease. 2019;25(9):1660-1667.

Return to reference 30

Reference 31

Public Health Agency of Canada. Case definitions for communicable diseases under national surveillance. CCDR. 2009;3552.

Return to reference 31

Reference 32

Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-fifth international supplement. CLSI. 2015.

Return to reference 32

Reference 33

Ehret JM, Nims LJ, Judson FN. A clinical isolate of Neisseria gonorrhoeae with in vitro resistance to erythromycin and decreased susceptibility to azithromycin. Sex Transm Dis. 1996;23(4):270-272.

Return to reference 33

Reference 34

Martin IMC, Ison CA, Aanensen DM, Fenton KA, Spratt BG. Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area. J Infect Dis. 2004;189(8):1497-1505.

Return to reference 34

Reference 35

Larkin MA, Blackshields G, Brown NP, et al. Clustal W and Clustal X version 2.0. Bioinformatics. 2007;23(21):2947-2948.

Return to reference 35

Reference 36

Tamura K, Nei M. Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol Biol Evol. 1993;10(3):512-526.

Return to reference 36

Reference 37

Public Health Agency of Canada. Report on the Enhanced Surveillance of Antimicrobial-Resistant Gonorrhea (ESAG):  Results from the 2014 pilot. 2018.

Return to reference 37

Reference 38

Public Health Agency of Canada. Report on the Enhanced Surveillance of Antimicrobial-Resistant Gonorrhea (ESAG):  Results from 2014 and 2015. 2019.

Return to reference 38

Reference 39

Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2007 supplement, Gonococcal Isolate Surveillance Project (GISP) annual reports 2007. 2007.

Return to reference 39

Appendix A

Neisseria gonorrhoeae Antimicrobial Resistance Criteria

Antibiotic Recommended Testing Concentration Ranges (mg/L) MIC Interpretive StandardAppendix A Footnote a Sources of Antibiotics
SAppendix A Footnote b DSAppendix A Footnote c IAppendix A Footnote d RAppendix A Footnote e
Penicillin 0.032 - 128.0 ≤ 0.06 - 0.12 - 1.0 ≥ 2.0 Sigma
Tetracycline 0.064 - 64.0 ≤ 0.25 - 0.5 - 1.0 ≥ 2.0 Sigma
Erythromycin 0.032 - 32.0 ≤ 1.0 - - ≥ 2.0 Sigma
Spectinomycin 4.0 - 256.0 ≤ 32.0 - 64.0 ≥ 128.0 Sigma
Ciprofloxacin 0.001 - 64.0 ≤ 0.06 - 0.12 - 0.5 ≥ 1.0 Bayer Health Care
Ceftriaxone 0.001 - 2.0 - ≥ 0.125 - - Sigma
Cefixime 0.002 - 2.0 - ≥ 0.25 - - Sigma
Azithromycin 0.016 - 32.0 ≤ 1.0 - - ≥ 2.0 Pfizer
Ertapenem 0.002 - 2.0 Interpretive Standards Not Available Sequoia
Gentamicin 0.5 - 128.0 Interpretive Standards Not Available MP Biomedicals
Appendix A Footnote a

MIC Interpretive Standards as recommended by the Clinical and Laboratory Standards Institute (CLSI 2015)32 except for erythromycin33, azithromycin39, and ceftriaxone and cefixime7.

Appendix A Return to footnote a referrer

Appendix A Footnote b

S = Susceptible

Appendix A Return to footnote b referrer

Appendix A Footnote c

DS = Decreased Susceptibility

Appendix A Return to footnote c referrer

Appendix A Footnote d

I = Intermediate

Appendix A Return to footnote d referrer

Appendix A Footnote e

R = Resistant

Appendix A Return to footnote e referrer

Appendix B

Neisseria gonorrhoeae Antimicrobial Resistance Characterization Definitions

Characterization Description Definition
PPNG Penicillinase Producing Neisseria gonorrhoeae Pen MIC ≥ 2.0 mg/L, ß-lactamase plasmid (3.05, 3.2 or 4.5 Mdal plasmid)
TRNG Tetracycline Resistant Neisseria gonorrhoeae Tet MIC ≥ 16.0 mg/L, 25.2 Mdal plasmid, TetM PCR positive
CMRNG Chromosomal Medicated Resistant Neisseria gonorrhoeae Pen MIC ≥ 2.0 mg/L, Tet MIC ≥ 2.0 mg/L but ≤ 8.0 mg/L, and Ery MIC ≥ 2.0 mg/L
Probable CMRNG Probable Chromosomal Mediated Resistant Neisseria gonorrhoeae One of the MIC values of Pen, Tet, Ery = 1 mg/L, the other two ≥ 2.0 mg/L
PenR Penicillin Resistant Neisseria gonorrhoeae Pen MIC ≥ 2.0 mg/L, ß-lactamase negative
TetR Tetracycline Resistant Neisseria gonorrhoeae Tet MIC ≥ 2.0 mg/L but ≤ 8.0 mg'L
EryR Erythromycin Resistant Neisseria gonorrhoeae Ery MIC ≥ 2.0 mg/L
CipR Ciprofloxacin Resistant Neisseria gonorrhoeae Cip MIC ≥ 1.0 mg/L
AzR Azithromycin Resistant Neisseria gonorrhoeae Az MIC ≥ 2.0 mg/L
SpecR Spectinomycin Resistant Neisseria gonorrhoeae Spec R ≥ 128 mg/L
CxDS Neisseria gonorrhoeae with decreased susceptibility to Ceftriaxone Cx MIC ≥ 0.125 mg/L
CeDS Neisseria gonorrhoeae with decreased susceptibility to Cefixime Ce MIC ≥ 0.25 mg/L
MDR-GC Multidrug-resistant gonococci Decreased susceptibility/Resistance to one currently recommended therapy (cephalosporin OR azithromycin) PLUS resistance to at least 2 other antimicrobials (penicillin, tetracycline, erythromycin, ciprofloxacin)
XDR-GC Extensively drug-resistant gonococci Decreased susceptibility/Resistance to two currently recommended therapies (cephalosporin AND azithromycin) plus resistance to at least two other antimicrobials (penicillin, tetracycline, erythromycin, ciprofloxacin)

Appendix C

Distribution of Antimicrobial Resistance by Sex or Sexual Behaviour, ESAG 2015-2017Appendix c Footnote b

Antimicrobial Resistance 2015 2016 2017
N % N % N %
gbMSM Male
CefiximeDS 3 0.8 0 0.0 1 0.3
CeftriaxoneDS 11 2.8 2 0.6 2 0.6
AzithromycinR 1 0.3 9 2.8 8 2.3
CiprofloxacinR 184 46.5 161 49.2 109 31.3
TetracyclineR 285 72.0 190 58.1 102 29.3
PenicillinR 85 21.5 44 13.5 18 5.2
ErythromycinR 168 42.4 98 30.0 52 14.9
SpectinomycinR 0 0.0 0 0.0 0 0.0
Susceptible to all antibiotics tested 88 22.2 96 29.4 174 50.0
Total gbMSM Male 396 327 348
Non-gbMSM Male
CefiximeDS 1 0.4 0 0.0 0 0.0
CeftriaxoneDS 1 0.4 1 0.5 0 0.0
AzithromycinR 1 0.4 0 0.0 2 0.7
CiprofloxacinR 31 13.8 82 38.7 67 24.7
TetracyclineR 113 50.4 120 56.6 143 52.8
PenicillinR 24 10.7 30 14.2 15 5.5
ErythromycinR 27 12.1 45 21.2 34 12.5
SpectinomycinR 0 0.0 0 0.0 0 0.0
Susceptible to all antibiotics tested 107 47.8 80 37.7 96 35.4
Total Non-gbMSM Male 224 212 271
Female
CefiximeDS 0 0.0 0 0.0 1 0.7
CeftriaxoneDS 0 0.0 1 0.7 0 0.0
AzithromycinR 1 0.6 4 2.9 2 1.4
CiprofloxacinR 22 13.1 50 35.7 36 25.0
TetracyclineR 74 44.0 75 53.6 79 54.9
PenicillinR 9 5.4 27 19.3 10 6.9
ErythromycinR 13 7.7 33 23.6 16 11.1
SpectinomycinR 0 0.0 0 0.0 0 0.0
Susceptible to all antibiotics tested 90 53.6 58 41.4 50 34.7
Total Female 168 140 144
OverallAppendix C Footnote a
CefiximeDS 6 0.8 0 0.0 2 0.3
CeftriaxoneDS 14 1.8 4 0.6 3 0.4
AzithromycinR 3 0.4 13 1.9 12 1.6
CiprofloxacinR 239 30.1 297 43.4 215 27.9
TetracyclineR 477 60.1 388 56.7 328 42.5
PenicillinR 120 15.1 102 14.9 44 5.7
ErythromycinR 211 26.6 176 25.7 104 13.5
SpectinomycinR 0 0.0 0 0.0 0 0.0
Susceptible to all antibiotics tested 285 35.9 234 34.2 322 41.8
Total Overall 794 684 771
DS:  Decreased Susceptibility, R:  Resistance
Appendix C Footnote a

Overall numbers include data from cases where sex or sexual behaviour were not provided (2015=6; 2016=5; and 2017=8).

Appendix C Return to footnote a referrer

Appendix C Footnote b

Includes duplicates.

Appendix C Return to footnote b referrer

Appendix D

Distribution of Antimicrobial Resistance by Sex and Infection Site, ESAG 2015-2017

2015 TotalsAppendix D1 Footnote a
CefiximeDS CeftriaxoneDS AzithromycinR PenicillinR TetracyclineR ErythromycinR CiprofloxacinR
N % N % N % N % N % N % N %
Female 168 0 0.0 0 0.0 1 0.6 9 5.4 74 44.0 13 7.7 22 13.1
Cervix 79 0 0.0 0 0.0 0 0.0 5 6.3 34 43.0 6 7.6 8 10.1
Pharynx 52 0 0.0 0 0.0 1 1.9 3 5.8 27 51.9 5 9.6 10 19.2
Rectum 37 0 0.0 0 0.0 0 0.0 1 2.7 13 35.1 2 5.4 4 10.8
Male 626 6 1.0 14 2.2 2 0.3 111 17.7 403 64.4 198 31.6 217 34.7
Urethra 354 2 0.6 2 0.6 2 0.6 49 13.8 208 58.8 76 21.5 89 25.1
Pharynx 125 4 3.2 8 6.4 0 0.0 24 19.2 86 68.8 54 43.2 58 46.4
Rectum 147 0 0.0 4 2.7 0 0.0 38 25.9 109 74.1 68 46.3 70 47.6
DS:  Decreased Susceptibility; R:  Resistance
Appendix D1 Footnote a

Includes duplicates

Appendis D1 Return to footnote a referrer

2016 TotalsAppendix D2 Footnote a
  CefiximeDS CeftriaxoneDS AzithromycinR PenicillinR TetracyclineR ErythromycinR CiprofloxacinR
N % N % N % N % N % N % N %
Female 140 0 0.0 1 0.7 4 2.9 27 19.3 75 53.6 33 23.6 50 35.7
Cervix 48 0 0.0 0 0.0 3 6.3 5 10.4 23 47.7 8 16.7 10 20.8
Pharynx 57 0 0.0 0 0.0 1 1.8 14 24.6 34 59.6 19 33.3 24 42.1
Rectum 35 0 0.0 1 2.9 0 0.0 8 22.9 18 51.4 6 17.1 16 45.7
Male 542 0 0.0 4 0.6 9 1.7 74 13.7 311 57.4 143 26.4 245 45.2
Urethra 295 0 0.0 2 0.7 3 1.0 48 14.9 169 57.3 72 24.4 124 42.0
Pharynx 111 0 0.0 0 0.0 4 3.6 14 12.6 61 55.0 31 27.9 55 49.5
Rectum 136 0 0.0 1 0.7 2 1.5 16 11.8 81 59.6 40 29.4 66 48.5
DS:  Decreased Susceptibility; R:  Resistance
Appendix D2 Footnote a

Includes duplicates

Appendis D2 Return to footnote a referrer

2017 TotalsAppendix D3 Footnote a
  CefiximeDS CeftriaxoneDS AzithromycinR PenicillinR TetracyclineR ErythromycinR CiprofloxacinR
N % N % N % N % N % N % N %
Female 144 1 0.7 0 0.0 2 1.4 10 6.9 79 54.9 16 11.1 36 25.0
Cervix 39 0 0.0 0 0.0 1 2.6 3 7.7 12 30.8 2 5.1 7 17.9
Pharynx 59 1 1.7 0 0.0 1 1.7 5 8.5 37 62.7 11 18.6 22 37.3
Rectum 45 0 0.0 0 0.0 0 0.0 2 4.4 29 64.4 2 4.4 6 13.3
Male 627 1 0.2 3 0.5 10 1.6 34 5.4 249 39.7 88 14.0 179 28.5
Urethra 364 0 0.0 1 0.3 3 0.8 16 4.4 161 44.2 47 12.9 91 25.0
Pharynx 152 1 0.7 2 1.3 6 3.9 17 11.2 52 34.2 26 17.1 53 34.9
Rectum 111 0 0.0 0 0.0 1 0.9 1 0.9 36 32.4 15 13.5 35 31.5
DS:  Decreased Susceptibility; R:  Resistance
Appendix D3 Footnote a

Includes duplicates

Appendis D3 Return to footnote a referrer

Appendix E

Full List of Treatments Used by Treatment Category, ESAG 2015-2017

  2015 2016 2017
AnogenitalAppendix E Footnote a gbMSM
(P) Ceftriaxone 250 mg, Azithromycin 1 g 175 182 161
(A) Cefixime 800 mg, Azithromycin 1 g 10 8 6
(A) Azithromycin 2 g 6 12 10
(N) Ceftriaxone 250 mg, Doxycycline 100 mg 0 13 14
(N) Ceftriaxone 250 mg, Azithromycin 1 g, Doxycycline 100 mg 0 2 5
(N) Ceftriaxone 250 mg, Azithromycin 1 g, Other 2 1 0
(N) Ceftriaxone 250 mg, Other 0 0 2
(N) Ceftriaxone 250 mg, Cefixime 800 mg, Azithromycin 1 g 1 0 1
(N) Cefixime 400 mg, Azithromycin 1 g 1 0 0
(N) Ceftriaxone 250 mg, Azithromycin 1 g, Ciprofloxacin 500 mg 1 0 0
(N) Ceftriaxone 125 mg, Azithromycin 1 g 1 0 0
(N) Doxycycline 100 mg 0 2 0
(N) Azithromycin 1 g 1 0 0
(N) Ciprofloxacin 500 mg 1 0 0
Unknown 1 0 0
AnogenitalAppendix E Footnote a Other AdultsAppendix E Footnote b
(P) Cefixime 800 mg, Azithromycin 1 g 235 243 302
(P) Ceftriaxone 250 mg, Azithromycin 1 g 26 12 10
(A) Azithromycin 2 g 7 11 10
(N) Ceftriaxone 250 mg, Cefixime 800 mg, Azithromycin 1 g 6 0 0
(N) Ceftriaxone 250 mg, Other 1 0 5
(N) Cefixime 800 mg, Doxycycline 100 mg 0 1 3
(N) Ceftriaxone 250 mg, Doxycycline 100 mg 0 2 2
(N) Ceftriaxone 250 mg, Cefixime 800 mg, Azithromycin 1 g, Doxycycline 100 mg 0 0 2
(N) Cefixime 800 mg, Other 1 1 0
(N) Ceftriaxone 250 mg, Azithromycin 1 g, Other 1 0 1
(N) Azithromycin 1 g, Azithromycin 2 g 0 0 2
(N) Cefixime 800 mg, Azithromycin 1 g, Azithromycin 2 g 0 0 1
(N) Ceftriaxone 250 mg, Doxycycline 100 mg, Other 0 1 0
(N) Ceftriaxone 250 mg, Ciprofloxacin 500 mg, Other 1 0 0
(N) Cefixime 400 mg, Azithromycin 1 g 1 0 0
(N) Azithromycin 2 g, Doxycycline 100 mg 0 0 1
(N) Doxycycline 100 mg, Other 0 1 0
(N) Ceftriaxone 250 mg, Cefixime 800 mg, Other 1 0 0
(N) Cefixime 400 mg, Cefixime 800 mg, Azithromycin 1 g 0 1 0
(N) Cefixime 400 mg, Cefixime 800 mg, Azithromycin 1 g 1 0 0
(N) Ceftriaxone 250 mg, Azithromycin 2 g, Doxycycline 100 mg 0 0 1
(N) Cefixime 800 mg, Ceftriaxone 250 mg, Azithromycin 1 g 0 0 1
(N) Cefixime 400 mg, Cefixime 800 mg, Ceftriaxone 250 mg, Azithromycin 1 g 1 0 0
(N) Ceftriaxone 250 mg, Cefixime 800 mg, Azithromycin 1 g 0 0 1
(N) Ceftriaxone 250 mg, Azithromycin 1 g, Doxycycline 100 mg 0 1 0
(N) Doxycycline 100 mg 1 4 0
(N) Azithromycin 1 g 2 1 0
(N) Cefixime 800 mg 1 1 1
Unknown 1 0 0
Pharyngeal gbMSM
(P) Ceftriaxone 250 mg, Azithromycin 1 g 108 84 124
(A) Cefixime 800 mg, Azithromycin 1 g 2 5 4
(N) Ceftriaxone 250 mg, Doxycycline 100 mg 1 5 7
(N) Ceftriaxone 250 mg, Azithromycin 1 g, Doxycycline 100 mg 0 0 3
(N) Ceftriaxone 250 mg, Other 2 0 0
(N) Ceftriaxone 250 mg, Azithromycin 2 g, Doxycycline 100 mg 0 2 0
(N) Azithromycin 2 g, Ciprofloxacin 500 mg 0 0 1
(N) Cefixime 800 mg, Azithromycin 2 g 0 0 1
(N) Ceftriaxone 250 mg, Ciprofloxacin 500 mg 1 0 0
(N) Ceftriaxone 250 mg, Azithromycin 1 g 0 1 0
(N) Azithromycin 1 g, Spectinomycin 2 g 1 0 0
(N) Ceftriaxone 250 mg, Azithromycin 1 g, Ciprofloxacin 500 mg, Doxycycline 100 mg 0 1 0
(N) Ciprofloxacin 500 mg, Other 1 0 0
(N) Azithromycin 1 g, Other 0 0 1
(N) Ceftriaxone 250 mg, Azithromycin 1 g, Other 0 0 1
(N) Azithromycin 2 g 3 2 3
(N) Doxycycline 100 mg 0 1 0
Pharyngeal Other AdultsAppendix E Footnote b
(P) Ceftriaxone 250 mg, Azithromycin 1 g 11 14 22
(A) Cefixime 800 mg, Azithromycin 1 g 29 31 29
(A) Azithromycin 2 g 3 7 2
(N) Ceftriaxone 250 mg, Doxycycline 100 mg 0 2 4
(N) Ceftriaxone 250 mg, Cefixime 800 mg, Azithromycin 1 g 4 0 0
(N) Ceftriaxone 250 mg, Other 1 0 1
(N) Ceftriaxone 250 mg, Ciprofloxacin 500 mg 0 1 0
(N) Cefixime 800 mg, Ceftriaxone 250 mg, Azithromycin 1 g 0 1 0
(N) Ceftriaxone 250 mg, Azithromycin 1 g, Azithromycin 2 g 1 0 0
(N) Cefixime 800 mg, Azithromycin 1 g, Doxycycline 100 mg 0 0 1
(N) Ceftriaxone 250 mg, Azithromycin 1 g, Other 0 0 1
(N) Ciprofloxacin 500 mg, Spectinomycin 2 g 1 0 0
(N) Azithromycin 2 g, Spectinomycin 2 g, Other 0 0 1
(N) Ceftriaxone 250 mg, Cefixime 800 mg, Azithromycin 1 g, Doxycycline 100 mg 1 0 0
(N) Doxycycline 100 mg 0 3 0
(N) Azithromycin 1 g 1 1 0
(N) Cefixime 800 mg 1 0 0
Unknown 3 0 0
(P) Preferred treatment in the Canadian Guidelines on Sexually Transmitted Infections – Gonococcal Infections Chapter, Revised July 2013 (treatment guidelines)1.
(A) Alternative treatment in the treatment guidelines.
(N) Not recommended in the treatment guidelines.
Appendix E Footnote a

Anogenital infections include genital and rectal infections.

Appendix E Return to footnote a referrer

Appendix E Footnote b

Other Adults include non-gbMSM males, females and transgendered. It does not include males with unknown sexual behavior or unknown sex.

Appendix E Return to footnote b referrer

Footnotes

Footnote a

MDR-GC:  decreased susceptibility/resistance to one currently recommended therapy (cephalosporin or azithromycin) PLUS resistance to at least two other antimicrobials (penicillin, tetracycline, erythromycin, ciprofloxacin)11.

Return to footnote a referrer

Footnote b

XDR-GC:  decreased susceptibility/resistance to two currently recommended therapies (cephalosporin and azithromycin) PLUS resistance to at least two other antimicrobials (penicillin, tetracycline, erythromycin, ciprofloxacin)11.

Return to footnote b referrer

Footnote c

In the absence of a pan-Canadian consensus on the definition of treatment failure, the proposed case definition for treatment failure is the absence of sexual contact AND one of the following:  (1) gram-negative intracellular diplococci at least 72 hours post treatment7 (2) positive N. gonorrhoeae culture at least 72 hours post treatment; or (3) positive N. gonorrhoeae NAAT at least 2-3 weeks post treatment1.

Return to footnote c referrer

Footnote d

Cefixime, ceftriaxone and azithromycin are part of the preferred treatments for gonorrhea in Canada1.

Return to footnote d referrer

Footnote e

Other Adults include non-gbMSM males, females, and transgendered. It does not include males with unknown sexual behaviour or unknown sex.

Return to footnote e referrer

Page details

Date modified: